[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR101561332B1 - New organic compounds and organic electro luminescence device comprising the same - Google Patents

New organic compounds and organic electro luminescence device comprising the same Download PDF

Info

Publication number
KR101561332B1
KR101561332B1 KR1020120142810A KR20120142810A KR101561332B1 KR 101561332 B1 KR101561332 B1 KR 101561332B1 KR 1020120142810 A KR1020120142810 A KR 1020120142810A KR 20120142810 A KR20120142810 A KR 20120142810A KR 101561332 B1 KR101561332 B1 KR 101561332B1
Authority
KR
South Korea
Prior art keywords
group
compound
unsubstituted
synthesis
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020120142810A
Other languages
Korean (ko)
Other versions
KR20140074634A (en
Inventor
엄민식
이용환
백영미
신진용
박호철
이창준
김태형
Original Assignee
주식회사 두산
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 두산 filed Critical 주식회사 두산
Priority to KR1020120142810A priority Critical patent/KR101561332B1/en
Priority to PCT/KR2013/010483 priority patent/WO2014092351A1/en
Publication of KR20140074634A publication Critical patent/KR20140074634A/en
Application granted granted Critical
Publication of KR101561332B1 publication Critical patent/KR101561332B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/657Polycyclic condensed heteroaromatic hydrocarbons
    • H10K85/6572Polycyclic condensed heteroaromatic hydrocarbons comprising only nitrogen in the heteroaromatic polycondensed ring system, e.g. phenanthroline or carbazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/40Organosilicon compounds, e.g. TIPS pentacene
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/615Polycyclic condensed aromatic hydrocarbons, e.g. anthracene
    • H10K85/622Polycyclic condensed aromatic hydrocarbons, e.g. anthracene containing four rings, e.g. pyrene
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/631Amine compounds having at least two aryl rest on at least one amine-nitrogen atom, e.g. triphenylamine
    • H10K85/633Amine compounds having at least two aryl rest on at least one amine-nitrogen atom, e.g. triphenylamine comprising polycyclic condensed aromatic hydrocarbons as substituents on the nitrogen atom
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/654Aromatic compounds comprising a hetero atom comprising only nitrogen as heteroatom
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/657Polycyclic condensed heteroaromatic hydrocarbons
    • H10K85/6576Polycyclic condensed heteroaromatic hydrocarbons comprising only sulfur in the heteroaromatic polycondensed ring system, e.g. benzothiophene
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1003Carbocyclic compounds
    • C09K2211/1007Non-condensed systems
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1003Carbocyclic compounds
    • C09K2211/1011Condensed systems
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1029Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1044Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1059Heterocyclic compounds characterised by ligands containing three nitrogen atoms as heteroatoms
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1092Heterocyclic compounds characterised by ligands containing sulfur as the only heteroatom
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K2101/00Properties of the organic materials covered by group H10K85/00
    • H10K2101/10Triplet emission
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/11OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

본 발명은 하기 화학식 1로 표시되는 화합물 및 이를 포함하는 유기 전계 발광 소자에 관한 것으로서, 하기 화학식 1로 표시되는 화합물을 하나 이상의 유기층, 바람직하게는 발광층에 포함함으로써, 소자의 발광효율, 구동 전압, 수명 등이 향상될 수 있다:
[화학식 1]

Figure 112012102405784-pat00131

(상기 화학식 1에서, R1 내지 R5 및 Ar1 은 각각 상세한 설명에서 정의한 바와 같음).The present invention relates to a compound represented by the following general formula (1) and an organic electroluminescent device comprising the same, wherein the compound represented by the following general formula (1) is contained in at least one organic layer, preferably a light emitting layer, Life and the like can be improved:
[Chemical Formula 1]
Figure 112012102405784-pat00131

(Wherein R 1 to R 5 and Ar 1 are each as defined in the detailed description).

Description

신규 유기 화합물 및 이를 포함하는 유기 전계 발광 소자{NEW ORGANIC COMPOUNDS AND ORGANIC ELECTRO LUMINESCENCE DEVICE COMPRISING THE SAME}TECHNICAL FIELD [0001] The present invention relates to a novel organic compound and an organic electroluminescent device including the organic compound. [0002]

본 발명은 유기 전계 발광 소자용 재료로서 사용될 수 있는 신규 유기 화합물 및 이를 포함하는 유기 전계 발광 소자에 관한 것이다.The present invention relates to a novel organic compound that can be used as a material for an organic electroluminescence device and an organic electroluminescence device including the same.

1950년대 Bernanose의 유기 박막 발광 관측을 시점으로 하여, 1965년 안트라센 단결정을 이용한 청색 전기발광으로 유기 전계 발광(electroluminescent, EL) 소자(이하, 간단히 '유기 EL 소자'로 칭함)에 대한 연구가 이어져 왔다. 1987년 탕(Tang)에 의하여 정공층과 발광층의 기능층으로 나눈 적층구조의 유기 EL 소자가 제시되었다. 이후, 고효율, 고수명의 유기 EL 소자를 만들기 위하여, 소자 내 각각의 특징적인 유기물 층을 도입하는 형태로 발전하여 왔으며, 이에 사용되는 특화된 물질의 개발로 이어졌다. Studies on organic electroluminescent (EL) devices (hereinafter, simply referred to as 'organic EL devices') by blue electroluminescence using anthracene single crystals in 1965 have been carried out with reference to the observation of organic thin film luminosity of Bernanose in the 1950s . In 1987, a layered organic EL device was proposed by Tang divided into a hole layer and a functional layer of a light emitting layer. Thereafter, in order to make a high efficiency and high number of organic EL devices, each organic EL device has been developed in a manner of introducing each characteristic organic material layer in the device, leading to the development of specialized materials used therefor.

유기 전계 발광 소자에서는 두 전극 사이에 전압을 걸어 주면 양극에서는 정공이 유기물층으로 주입되고, 음극에서는 전자가 유기물층으로 주입된다. 주입된 정공과 전자가 만났을 때 엑시톤(exciton)이 형성되며, 이 엑시톤이 바닥상태로 떨어질 때 빛이 나게 된다. 이때, 유기물층으로 사용되는 물질은 그 기능에 따라, 발광 물질, 정공 주입 물질, 정공 수송 물질, 전자 수송 물질, 전자 주입 물질 등으로 분류될 수 있다. In the organic electroluminescent device, when a voltage is applied between two electrodes, holes are injected into the organic layer in the anode, and electrons are injected into the organic layer in the cathode. When the injected holes and electrons meet, an exciton is formed. When the exciton falls to the ground state, light is emitted. At this time, the material used as the organic material layer can be classified into a light emitting material, a hole injecting material, a hole transporting material, an electron transporting material, an electron injecting material and the like depending on its function.

발광 물질은 발광색에 따라 청색, 녹색, 적색 발광 물질과, 보다 나은 천연색을 구현하기 위해 필요한 노란색 및 주황색 발광 물질로 구분될 수 있다. 또한, 색순도의 증가와 에너지 전이를 통한 발광 효율을 증가시키기 위하여, 발광 물질로서 호스트/도판트 계를 사용할 수 있다. The luminescent material can be classified into blue, green and red luminescent materials according to luminescent colors and yellow and orange luminescent materials necessary for realizing better natural colors. Further, in order to increase the color purity and to increase the luminous efficiency through energy transfer, a host / dopant system can be used as a luminescent material.

도판트 물질은 유기 물질을 사용하는 형광 도판트와 Ir, Pt 등의 중원자(heavy atoms)가 포함된 금속 착체 화합물을 사용하는 인광 도판트로 나눌 수 있다. 이때, 인광 재료는 이론적으로 형광 재료에 비해 최대 4배의 발광 효율을 향상시킬 수 있기 때문에, 인광 도판트 뿐만 아니라 인광 호스트 재료들에 대한 연구가 많이 진행되고 있다. The dopant material can be divided into a fluorescent dopant using an organic material and a phosphorescent dopant using a metal complex compound containing heavy atoms such as Ir and Pt. Since the phosphorescent material can theoretically improve the luminous efficiency up to 4 times as much as that of the fluorescent material, studies on phosphorescent host materials as well as phosphorescent dopants have been conducted.

현재까지 정공 주입층, 정공 수송층, 정공 차단층, 전자 수송층으로는 NPB, BCP, Alq3 등이 널리 알려져 있으며, 발광 재료로는 안트라센 유도체들이 형광 도판트/호스트 재료로서 보고되고 있다. 특히, 발광 재료 중 효율 향상 측면에서 큰 장점을 가지고 있는 인광 재료들은 청색(blue), 녹색(green), 적색(red) 도판트 재료로서 Firpic, Ir(ppy)3, (acac)Ir(btp)2 등의 Ir을 포함하는 금속 착체 화합물이 사용되고 있다. 현재까지는 4,4-dicarbazolybiphenyl(CBP)가 인광 호스트 재료로서 우수한 특성을 나타내고 있다.Until now, NPB, BCP, and Alq 3 have been widely known as a hole injecting layer, a hole transporting layer, a hole blocking layer, and an electron transporting layer. Anthracene derivatives as a light emitting material have been reported as fluorescent dopant / host materials. Particularly, phosphorescent materials which have a great advantage in terms of efficiency improvement of light emitting materials include Firpic, Ir (ppy) 3 , (acac) Ir (btp) as a blue, green, 2 or the like is used. Up to now, 4,4-dicarbazolybiphenyl (CBP) has shown excellent properties as a phosphorescent host material.

그러나, 기존의 재료들은 발광 특성 측면에서는 유리한 면이 있으나, 유리전이온도가 낮아 열적 안정성이 떨어지기 때문에, OLED 소자에서의 수명 측면에서 만족할 만한 수준이 되지 못하는 실정이다. 따라서, 보다 성능이 뛰어난 재료의 개발이 요구되고 있다.However, existing materials have an advantage in terms of light emission characteristics, but their thermal stability is lowered due to their low glass transition temperature, so that they are not satisfactory in terms of lifetime in OLED devices. Therefore, development of materials with higher performance is required.

일본 공개특허공보 특개2001-160489Japanese Patent Application Laid-Open No. 2001-160489

본 발명은 높은 유리 전이온도로 인해 열적 안정성이 우수하면서, 정공과 전자의 결합력을 향상시킬 수 있는 신규 유기 화합물을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a novel organic compound capable of improving the bonding force between holes and electrons while having excellent thermal stability due to a high glass transition temperature.

또, 본 발명은 상기 신규 유기 화합물을 포함하여 구동전압, 발광효율 등이 향상된 유기 전계 발광 소자를 제공하는 것을 목적으로 한다.It is another object of the present invention to provide an organic electroluminescent device including the novel organic compound and having improved driving voltage, luminous efficiency, and the like.

본 발명은 하기 화학식 1로 표시되는 화합물을 제공한다:The present invention provides a compound represented by the following formula (1): < EMI ID =

Figure 112012102405784-pat00001
Figure 112012102405784-pat00001

상기 화학식 1에서,In Formula 1,

R1 내지 R5는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소, 할로겐, 시아노, 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기, 치환 또는 비치환된 C6~C40의 아릴아민기, 치환 또는 비치환된 C3~C40의 시클로알킬기, 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기, 치환 또는 비치환된 C1~C40의 알킬실릴기, 치환 또는 비치환된 C1~C40의 알킬보론기, 치환 또는 비치환된 C6~C40의 아릴보론기, 치환 또는 비치환된 C6~C40의 아릴포스핀기, 치환 또는 비치환된 C6~C40의 아릴포스핀옥사이드기, 및 치환 또는 비치환된 C6~C40의 아릴실릴기로 이루어진 군에서 선택되거나, 또는 인접하는 기와 결합하여 축합 고리를 형성할 수 있으며,R 1 to R 5 are the same or different and each independently represents hydrogen, deuterium, halogen, cyano, substituted or unsubstituted C 1 to C 40 alkyl, substituted or unsubstituted C 2 to C 40 alkenyl , A substituted or unsubstituted C 2 to C 40 alkynyl group, a substituted or unsubstituted C 6 to C 40 aryl group, a substituted or unsubstituted heteroaryl group having 5 to 40 nucleus atoms, a substituted or unsubstituted A C 6 to C 40 aryloxy group, a substituted or unsubstituted C 1 to C 40 alkyloxy group, a substituted or unsubstituted C 6 to C 40 arylamine group, a substituted or unsubstituted C 3 to C 40 A substituted or unsubstituted C 1 to C 40 alkylsilyl group, a substituted or unsubstituted C 1 to C 40 alkylboron group, a substituted or unsubstituted C 1 to C 40 alkylcarbonyl group, a substituted or unsubstituted heterocycloalkyl group having 3 to 40 nucleus atoms, a substituted or unsubstituted C 1 to C 40 alkylsilyl group, substituted or unsubstituted C 6 ~ C 40 aryl boron group, a substituted or unsubstituted C 6 ~ C 40 aryl phosphine group, a substituted or unsubstituted C 6 ~ C 40 ring An aryl phosphine oxide group, and a substituted or unsubstituted C 6 to C 40 arylsilyl group, or may be bonded to an adjacent group to form a condensed ring,

다만, R1 및 R2, R2 및 R3, R3 및 R4 중 적어도 하나는 서로 결합하여 하기 화학식 2로 표시되는 축합고리를 형성하고,Provided that at least one of R 1 and R 2, R 2 and R 3 , R 3 and R 4 is bonded to each other to form a condensed ring represented by the following formula (2)

Figure 112012102405784-pat00002
Figure 112012102405784-pat00002

상기 화학식 2에서,In Formula 2,

점선은 화학식 1의 R1 및 R2, R2 및 R3, R3 및 R4 중 적어도 하나와 결합하여 축합이 이루어지는 부위를 의미하며;The dotted line means a moiety in which at least one of R 1 and R 2, R 2 and R 3 , R 3 and R 4 in Formula 1 is bonded to form a condensation;

X1은 O, S, Se, N(Ar2), C(Ar3)(Ar4) 및 Si(Ar5)(Ar6)으로 이루어진 군에서 선택되고;X 1 is selected from the group consisting of O, S, Se, N (Ar 2 ), C (Ar 3 ) (Ar 4 ) and Si (Ar 5 ) (Ar 6 );

Ar1 내지 Ar6는 각각 독립적으로 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기, 치환 또는 비치환된 C6~C40의 아릴아민기, 치환 또는 비치환된 C3~C40의 시클로알킬기, 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기, 치환 또는 비치환된 C1~C40의 알킬실릴기, 치환 또는 비치환된 C1~C40의 알킬보론기, 치환 또는 비치환된 C6~C40의 아릴보론기, 치환 또는 비치환된 C6~C40의 아릴포스핀기, 치환 또는 비치환된 C6~C40의 아릴포스핀옥사이드기 및 치환 또는 비치환된 C6~C40의 아릴실릴기로 이루어진 군에서 선택되며;Ar 1 to Ar 6 each independently represent a substituted or unsubstituted C 1 to C 40 alkyl group, a substituted or unsubstituted C 2 to C 40 alkenyl group, a substituted or unsubstituted C 2 to C 40 alkynyl group, A substituted or unsubstituted C 6 to C 40 aryl group, a substituted or unsubstituted heteroaryl group having 5 to 40 nucleus atoms, a substituted or unsubstituted C 6 to C 40 aryloxy group, a substituted or unsubstituted C 1 ~ C 40 alkyloxy group, a substituted or unsubstituted C 6 ~ C 40 aryl amine group, a substituted or unsubstituted C 3 ~ C 40 cycloalkyl group, a substituted or unsubstituted nucleus atoms from 3 to 40 A substituted or unsubstituted C 1 to C 40 alkylsilyl group, a substituted or unsubstituted C 1 to C 40 alkylboron group, a substituted or unsubstituted C 6 to C 40 arylboron group, A substituted or unsubstituted C 6 to C 40 arylphosphine group, a substituted or unsubstituted C 6 to C 40 arylphosphine oxide group, and a substituted or unsubstituted C 6 to C 40 ≪ / RTI >

R6 내지 R9는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소, 할로겐, 시아노, 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기, 치환 또는 비치환된 C6~C40의 아릴아민기, 치환 또는 비치환된 C3~C40의 시클로알킬기, 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기, 치환 또는 비치환된 C1~C40의 알킬실릴기, 치환 또는 비치환된 C1~C40의 알킬보론기, 치환 또는 비치환된 C6~C40의 아릴보론기, 치환 또는 비치환된 C6~C40의 아릴포스핀기, 치환 또는 비치환된 C6~C40의 아릴포스핀옥사이드기 및 치환 또는 비치환된 C6~C40의 아릴실릴기로 이루어진 군에서 선택되거나, 또는 인접하는 기와 결합하여 축합 고리를 형성할 수 있으며;R 6 to R 9 are the same or different and each independently represents hydrogen, deuterium, halogen, cyano, substituted or unsubstituted C 1 to C 40 alkyl group, substituted or unsubstituted C 2 to C 40 alkenyl group , A substituted or unsubstituted C 2 to C 40 alkynyl group, a substituted or unsubstituted C 6 to C 40 aryl group, a substituted or unsubstituted heteroaryl group having 5 to 40 nucleus atoms, a substituted or unsubstituted A C 6 to C 40 aryloxy group, a substituted or unsubstituted C 1 to C 40 alkyloxy group, a substituted or unsubstituted C 6 to C 40 arylamine group, a substituted or unsubstituted C 3 to C 40 A substituted or unsubstituted C 1 to C 40 alkylsilyl group, a substituted or unsubstituted C 1 to C 40 alkylboron group, a substituted or unsubstituted C 1 to C 40 alkylcarbonyl group, a substituted or unsubstituted heterocycloalkyl group having 3 to 40 nucleus atoms, a substituted or unsubstituted C 1 to C 40 alkylsilyl group, substituted or unsubstituted C 6 ~ C 40 aryl boron group, a substituted or unsubstituted C 6 ~ C 40 aryl phosphine group, a substituted or unsubstituted C 6 ~ C 40 ring An aryl phosphine oxide group and a substituted or unsubstituted C 6 to C 40 arylsilyl group, or may be bonded to an adjacent group to form a condensed ring;

상기 R1 내지 R9, 및 Ar1 내지 Ar6의 알킬기, 알케닐기, 알키닐기, 아릴기, 헤테로아릴기, 아릴옥시기, 알킬옥시기, 아릴아민기, 시클로알킬기, 헤테로시클로알킬기, 알킬실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴실릴기에 각각 도입되는 하나 이상의 치환기는 각각 독립적으로 중수소, 할로겐, 시아노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, C1~C40의 알킬보론기, C6~C40의 아릴보론기, C6~C40의 아릴포스핀기, C6~C40의 아릴포스핀옥사이드기 및 C6~C40의 아릴실릴기로 이루어진 군으로부터 선택되고, 이때 치환기가 복수인 경우, 서로 동일하거나 상이할 수 있다.The R 1 to R 9 , And the alkyl group of Ar 1 to Ar 6, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aryloxy group, an alkyloxy group, an arylamine group, a cycloalkyl group, a heterocycloalkyl group, alkylsilyl group, an alkyl boron group, an aryl Halogen, cyano, a C 1 to C 40 alkyl group, a C 2 to C 40 alkenyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aryl group, C 2 ~ C 40 alkynyl group, C 6 ~ C 40 aryl group, an aryloxy group of nuclear atoms aryl of from 5 to 40 heteroaryl group, C 6 ~ C 40, alkyloxy group of C 1 ~ C 40 of, C A C 3 to C 40 cycloalkyl group, a C 3 to C 40 heterocycloalkyl group, a C 1 to C 40 alkylsilyl group, a C 1 to C 40 alkylboron group, a C 6 to C 40 arylamine group, a C 3 to C 40 cycloalkyl group, to 6 ~ C 40 aryl boron group, C 6 ~ C 40 aryl phosphine group, C 6 ~ C 40 aryl phosphine oxide group, and the group consisting of C 6 ~ C 40 aryl group in the silyl Emitter is selected, and wherein when the substituent is a plurality, may be identical to or different from each other.

또한, 본 발명은 양극, 음극, 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하는 유기 전계 발광 소자로서, 상기 1층 이상의 유기물층 중에서 적어도 하나는 상기 화합물을 포함하는 것이 특징인 유기 전계 발광 소자를 제공한다.Further, the present invention is an organic electroluminescent device comprising a cathode, a cathode, and one or more organic layers sandwiched between the anode and the cathode, wherein at least one of the one or more organic layers includes the compound An organic electroluminescent device is provided.

본 발명의 화학식 1로 표시되는 화합물은 열적 안정성 및 인광 특성이 우수하기 때문에, 유기 전계 발광 소자의 발광층에 적용될 수 있다.The compound represented by the general formula (1) of the present invention is excellent in thermal stability and phosphorescence properties and can be applied to a light emitting layer of an organic electroluminescent device.

따라서, 본 발명의 화학식 1로 표시되는 화합물을 인광 호스트 물질로 사용할 경우, 종래 호스트 물질에 비해 우수한 발광 성능, 낮은 구동전압, 높은 효율 및 장수명을 갖는 유기 전계 발광 소자를 제조할 수 있고, 나아가 성능, 수명이 크게 향상된 풀 칼라 디스플레이 패널도 제조할 수 있다. Accordingly, when the compound represented by Formula 1 of the present invention is used as a phosphorescent host material, it is possible to manufacture an organic electroluminescent device having excellent light emitting performance, low driving voltage, high efficiency and long life time as compared with the conventional host material, , And a full color display panel having a greatly improved lifetime can be manufactured.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명에 따른 신규 화합물은 인다졸 모이어티(indazole moiety)의 말단에 인돌(indole) 모이어티가 축합(fused)되어 기본 골격을 이루며, 이러한 기본 골격에 다양한 치환체가 결합된 구조로서, 상기 화학식 1로 표시되는 것을 특징으로 한다. 이러한 화학식 1로 표시되는 화합물은 종래 유기 EL 소자용 재료 [예: 4,4-dicarbazolybiphenyl (이하, 'CBP'로 표시함)]보다 분자량이 클 뿐만 아니라, 넓은 에너지 밴드갭을 가지면서, 정공과 전자의 결합력을 높일 수 있다. 따라서, 상기 화학식 1의 화합물을 유기 EL 소자에 이용할 경우, 소자의 구동 전압, 효율(발광효율, 전력효율), 수명 및 휘도 측면이 향상될 수 있다.The novel compound according to the present invention has a structure in which an indole moiety is fused at the terminal of an indazole moiety to form a basic skeleton and various substituents are bonded to the basic skeleton. . The compound represented by the formula (1) has a larger molecular weight than the conventional organic EL device materials (for example, 4,4-dicarbazolybiphenyl (hereinafter referred to as "CBP")] The bonding force of electrons can be increased. Accordingly, when the compound of Formula 1 is used in an organic EL device, the driving voltage, efficiency (luminous efficiency, power efficiency), lifetime and brightness of the device can be improved.

상기 화학식 1로 표시되는 화합물은 인다졸 모이어티(indazole moiety)의 말단에 결합된 인돌(indole) 모이어티로 인해서 넓은 밴드갭을 가질 수 있다. 뿐만 아니라, 상기 화합물은 상기 기본 골격에 결합된 다양한 방향족 환 치환체로 인해 분자 전체가 바이폴라(bipolar) 특성을 가지면서, 정공과 전자의 결합력을 높일 수 있다. 따라서, 유기 EL 소자에 상기 화합물을 적용할 경우, 종래 CBP에 비해 발광층의 호스트 재료로서의 우수한 특성을 나타낼 수 있기 때문에, 소자의 인광 특성이 개선됨과 동시에 정공 주입 능력 및/또는 수송 능력, 발광효율, 구동전압, 수명 특성 등이 개선될 수 있다. 그리고, 상기 치환체들에 따라 에너지 레벨이 조절될 수 있어 넓은 밴드갭(sky blue ~ red)을 갖게 되고, 따라서 발광층뿐만 아니라, 정공 수송층, 정공 주입층 등으로도 응용될 수 있다. The compound represented by Formula 1 may have a wide band gap due to an indole moiety bonded to the terminal of the indazole moiety. In addition, since the compound has bipolar characteristics as a whole due to various aromatic ring substituents bonded to the basic skeleton, the compound can increase the binding force between holes and electrons. Therefore, when the compound is applied to the organic EL device, the phosphorescent property of the device can be improved and the hole injecting ability and / or transporting ability, luminous efficiency, The driving voltage, the life characteristic, and the like can be improved. Further, the energy level can be controlled according to the above-mentioned substituents and thus has a wide band gap (sky blue ~ red), and thus can be applied not only to a light emitting layer but also to a hole transporting layer and a hole injecting layer.

또한, 상기 인돌(indole) 모이어티에 다수 도입된 다양한 방향족 환(aromatic ring) 치환체로 인해 화합물의 분자량이 유의적으로 증대됨으로써, 유리전이온도가 향상될 수 있고, 이로 인해 종래 CBP 보다 높은 열적 안정성을 가질 수 있다. 또한, 상기 인다졸 모이어티의 말단에 결합된 인돌(indole) 모이어티가 축합됨으로써. 화합물의 열적 안정성이 향상될 수 있을 뿐만 아니라, 상기 화학식 1의 화합물을 포함하는 유기층의 결정화 억제에도 효과가 있다. 따라서, 본 발명에 따른 화학식 1의 화합물을 포함하는 소자는 내구성 및 수명 특성을 크게 향상시킬 수 있다. In addition, due to various aromatic ring substituents introduced in many of the indole moieties, the molecular weight of the compound is significantly increased, so that the glass transition temperature can be improved, Lt; / RTI > Also, the indole moiety bonded to the end of the indazole moiety is condensed. Not only the thermal stability of the compound can be improved, but also the effect of inhibiting the crystallization of the organic layer containing the compound of the formula (1). Therefore, the device including the compound of Formula 1 according to the present invention can greatly improve durability and lifetime characteristics.

아울러, 본 발명에 따른 화학식 1의 화합물을 유기 EL 소자의 정공 주입/수송층 재료, 청색, 녹색 및/또는 적색의 인광 호스트 재료로 채택할 경우, 종래 CBP 대비 효율 및 수명 면에서 월등히 우수한 효과를 발휘할 수 있다. 따라서, 본 발명에 따른 화합물은 유기 EL 소자의 성능 개선 및 수명 향상에 크게 기여할 수 있으며, 특히 이러한 소자 수명 향상은 풀 칼라 유기 발광 패널에서의 성능 극대화에도 큰 효과가 있다.In addition, when the compound of Formula 1 according to the present invention is used as a positive hole injection / transport layer material, a blue, green and / or red phosphorescent host material of an organic EL device, it exerts an excellent effect in terms of efficiency and life . Therefore, the compound according to the present invention can greatly contribute to the improvement of the performance and lifetime of the organic EL device, and particularly the lifetime improvement of the device has a great effect for maximizing the performance in the full-color organic light emitting panel.

본 발명에 따른 화학식 1로 표시되는 화합물에서, R1 내지 R5는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소, 할로겐, 시아노, 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기, 치환 또는 비치환된 C6~C40의 아릴아민기, 치환 또는 비치환된 C3~C40의 시클로알킬기, 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기, 치환 또는 비치환된 C1~C40의 알킬실릴기, 치환 또는 비치환된 C1~C40의 알킬보론기, 치환 또는 비치환된 C6~C40의 아릴보론기, 치환 또는 비치환된 C6~C40의 아릴포스핀기, 치환 또는 비치환된 C6~C40의 아릴포스핀옥사이드기 및 치환 또는 비치환된 C6~C40의 아릴실릴기로 이루어진 군에서 선택되거나, 또는 인접하는 기와 결합하여 축합 고리를 형성할 수 있으며, In the compound represented by formula (1) according to the present invention, R 1 to R 5 are the same or different and each independently represents hydrogen, deuterium, halogen, cyano, substituted or unsubstituted C 1 to C 40 alkyl group Or an unsubstituted C 2 to C 40 alkenyl group, a substituted or unsubstituted C 2 to C 40 alkynyl group, a substituted or unsubstituted C 6 to C 40 aryl group, a substituted or unsubstituted nucleus atom number of 5 A substituted or unsubstituted C 6 to C 40 aryloxy group, a substituted or unsubstituted C 1 to C 40 alkyloxy group, a substituted or unsubstituted C 6 to C 40 arylamine A substituted or unsubstituted C 3 to C 40 cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group having 3 to 40 nuclear atoms, a substituted or unsubstituted C 1 to C 40 alkylsilyl group, hwandoen C 1 ~ C 40 alkyl boron group, a substituted or unsubstituted C 6 ~ C 40 aryl boron group, a substituted or unsubstituted C 6 ~ C 40 aryl phosphine group, a substituted or unsubstituted C 6 ~ C 40 aryl phosphine oxide group, and a substituted or unsubstituted selected from the group consisting arylsilyl of unsubstituted C 6 ~ C 40 of or, or adjacent groups combine to To form a condensed ring,

바람직하게는 R1 내지 R5는 수소, 중수소, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 및 치환 또는 비치환된 C6~C40의 아릴아민기로 이루어진 군에서 선택될 수 있다.Preferably, R 1 to R 5 are hydrogen, deuterium, a substituted or unsubstituted C 6 to C 40 aryl group, a substituted or unsubstituted heteroaryl group having 5 to 40 nucleus atoms, and a substituted or unsubstituted C And an arylamine group having 6 to 40 carbon atoms.

이때, 상기 R1 내지 R5의 알킬기, 알케닐기, 알키닐기, 아릴기, 헤테로아릴기, 아릴옥시기, 알킬옥시기, 아릴아민기, 시클로알킬기, 헤테로시클로알킬기, 알킬실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴실릴기에 각각 도입되는 하나 이상의 치환기는 각각 독립적으로 중수소, 할로겐, 시아노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C40의 아릴포스핀기, C6~C40의 아릴포스핀옥사이드기 및 C6~C40의 아릴실릴기로 이루어진 군으로부터 선택되되, 상기 치환기가 복수인 경우, 서로 동일하거나 상이할 수 있다.In this case, the alkyl group of the R 1 to R 5, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aryloxy group, an alkyloxy group, an arylamine group, a cycloalkyl group, a heterocycloalkyl group, alkylsilyl group, an alkyl boronic group , an aryl boron group, an aryl phosphine group, aryl phosphine oxide groups and arylsilyl groups or a salt thereof introduced respectively are each independently a heavy hydrogen, a halogen, cyano group, C 1 ~ C 40 alkyl group, C 2 ~ alkenyl of C 40 A C 2 to C 40 alkynyl group, a C 6 to C 40 aryl group, a heteroaryl group having 5 to 40 nuclear atoms, a C 6 to C 40 aryloxy group, a C 1 to C 40 alkyloxy group , A C 6 to C 40 arylamine group, a C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 1 to C 40 alkylsilyl group, a C 1 to C 40 alkylboron group , C 6 ~ C 60 aryl boron group, C 6 ~ C 40 aryl phosphine group, C 6 ~ C 40 aryl phosphine oxide group, and a C 6 ~ C 40 aryl silyl group consisting of Doedoe selected from, in the case where the substituent a plurality, may be identical to or different from each other.

다만, R1 및 R2, R2 및 R3, R3 및 R4 중 적어도 하나는 서로 결합하여 상기 화학식 2로 표시되는 축합고리를 형성한다. 예를 들어, 상기 R1 및 R2이 서로 결합하여 상기 화학식 2로 표시되는 축합 고리를 형성할 경우, 하기 화학식 3 또는 4로 표시되는 화합물이 형성된다.Provided that at least one of R 1 and R 2, R 2 and R 3 , R 3 and R 4 is bonded to each other to form a condensed ring represented by the general formula (2). For example, when R 1 and R 2 are bonded to each other to form a condensed ring represented by Formula 2, a compound represented by Formula 3 or 4 is formed.

상기 화학식 2에서 점선은 화학식 1의 R1 및 R2, R2 및 R3, R3 및 R4 중 적어도 하나와 축합이 이루어지는 부위를 의미한다.In the formula (2), the dotted line indicates a site where condensation is performed with at least one of R 1 , R 2, R 2 , R 3 , R 3, and R 4 in Chemical Formula 1.

상기 X1는 O, S, Se, N(Ar2), C(Ar3)(Ar4) 및 Si(Ar5)(Ar6)으로 이루어진 군에서 선택되고, 바람직하게는 N(Ar2)일 수 있다.Wherein X 1 is O, S, Se, N ( Ar 2), C (Ar 3) (Ar 4) and Si (Ar 5) is selected from the group consisting of (Ar 6), preferably N (Ar 2) Lt; / RTI >

상기 Ar1 내지 Ar6은 각각 독립적으로 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기, 치환 또는 비치환된 C6~C40의 아릴아민기, 치환 또는 비치환된 C3~C40의 시클로알킬기, 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기, 치환 또는 비치환된 C1~C40의 알킬실릴기, 치환 또는 비치환된 C1~C40의 알킬보론기, 치환 또는 비치환된 C6~C40의 아릴보론기, 치환 또는 비치환된 C6~C40의 아릴포스핀기, 치환 또는 비치환된 C6~C40의 아릴포스핀옥사이드기 및 치환 또는 비치환된 C6~C40의 아릴실릴기로 이루어진 군에서 선택된다.Each of Ar 1 to Ar 6 independently represents a substituted or unsubstituted C 1 to C 40 alkyl group, a substituted or unsubstituted C 2 to C 40 alkenyl group, a substituted or unsubstituted C 2 to C 40 alkynyl group , A substituted or unsubstituted C 6 to C 40 aryl group, a substituted or unsubstituted heteroaryl group having 5 to 40 nucleus atoms, a substituted or unsubstituted C 6 to C 40 aryloxy group, a C 1 ~ C 40 of the alkyloxy group, a substituted or unsubstituted C 6 ~ C 40 aryl amine group, a substituted or unsubstituted number of C 3 to a cycloalkyl group, a substituted or unsubstituted of C 40 unsubstituted nucleus atoms of 3 to A substituted or unsubstituted C 1 to C 40 alkylsilyl group, a substituted or unsubstituted C 1 to C 40 alkylboron group, a substituted or unsubstituted C 6 to C 40 arylboron group , substituted or unsubstituted C 6 ~ C 40 aryl phosphine group, a substituted or unsubstituted C 6 ~ C 40 aryl phosphine oxide group, and a substituted or unsubstituted C 6 of To C 40 arylsilyl groups.

이때, 상기 Ar1 내지 Ar6의 알킬기, 알케닐기, 알키닐기, 아릴기, 헤테로아릴기, 아릴옥시기, 알킬옥시기, 아릴아민기, 시클로알킬기, 헤테로시클로알킬기, 알킬실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴실릴기에 각각 도입되는 하나 이상의 치환기는 각각 독립적으로 중수소, 할로겐, 시아노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, C1~C40의 알킬보론기, C6~C40의 아릴보론기, C6~C40의 아릴포스핀기, C6~C40의 아릴포스핀옥사이드기 및 C6~C40의 아릴실릴기로 이루어진 군으로부터 선택되고, 다만 상기 치환기가 복수인 경우, 서로 동일하거나 상이할 수 있다.In this case, the alkyl group of said Ar 1 to Ar 6, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aryloxy group, an alkyloxy group, an arylamine group, a cycloalkyl group, a heterocycloalkyl group, alkylsilyl group, an alkyl boronic group , an aryl boron group, an aryl phosphine group, aryl phosphine oxide groups and arylsilyl groups or a salt thereof introduced respectively are each independently a heavy hydrogen, a halogen, cyano group, C 1 ~ C 40 alkyl group, C 2 ~ alkenyl of C 40 A C 2 to C 40 alkynyl group, a C 6 to C 40 aryl group, a heteroaryl group having 5 to 40 nuclear atoms, a C 6 to C 40 aryloxy group, a C 1 to C 40 alkyloxy group , A C 6 to C 40 arylamine group, a C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 1 to C 40 alkylsilyl group, a C 1 to C 40 alkylboron group , C 6 ~ C 40 aryl boron group, C 6 ~ C 40 aryl phosphine group, C 6 ~ C 40 aryl phosphine oxide group, and a C 6 ~ C 40 aryl silyl group consisting of , Provided that when a plurality of said substituents are plural, they may be the same as or different from each other.

바람직하게는 상기 Ar1 내지 Ar6은 각각 독립적으로 치환 또는 비치환된 C6~C40의 아릴기 및 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기로 이루어진 군으로부터 선택될 수 있다.Preferably, each of Ar 1 to Ar 6 is independently selected from the group consisting of a substituted or unsubstituted C 6 to C 40 aryl group and a substituted or unsubstituted heteroaryl group having 5 to 40 nucleus atoms.

이때, 상기 Ar1 내지 Ar6의 아릴기 및 헤테로아릴기에 각각 도입되는 하나 이상의 치환기는 각각 독립적으로 중수소, 할로겐, 시아노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, 및 C6~C40의 아릴실릴기로 이루어진 군으로부터 선택되고, 다만 상기 치환기가 복수인 경우, 서로 동일하거나 상이할 수 있다.In this case, one or more substituents respectively introduced into the aryl group and the heteroaryl group of Ar 1 to Ar 6 are each independently selected from the group consisting of deuterium, halogen, cyano, C 1 to C 40 alkyl, C 2 to C 40 alkenyl, C 2 ~ C 40 alkynyl group, C 6 ~ C 40 aryl group, an aryloxy group of nuclear atoms aryl of from 5 to 40 heteroaryl group, a C 6 ~ C 40, alkyloxy group of C 1 ~ C 40 of, C 6 ~ C 40 aryl amine group, a C 3 ~ C 40 cycloalkyl group, the nuclear atoms of 3 to 40 heterocycloalkyl group, C 1 ~ C 40 alkyl silyl group, and a C 6 ~ C 40 group consisting arylsilyl of , Provided that when the substituents are plural, they may be the same or different.

R6 내지 R9는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소, 할로겐, 시아노, 치환 또는 비치환된 C1~C40의 알킬기, 치환 또는 비치환된 C2~C40의 알케닐기, 치환 또는 비치환된 C2~C40의 알키닐기, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기, 치환 또는 비치환된 C6~C40의 아릴옥시기, 치환 또는 비치환된 C1~C40의 알킬옥시기, 치환 또는 비치환된 C6~C40의 아릴아민기, 치환 또는 비치환된 C3~C40의 시클로알킬기, 치환 또는 비치환된 핵원자수 3 내지 40의 헤테로시클로알킬기, 치환 또는 비치환된 C1~C40의 알킬실릴기, 치환 또는 비치환된 C1~C40의 알킬보론기, 치환 또는 비치환된 C6~C40의 아릴보론기, 치환 또는 비치환된 C6~C40의 아릴포스핀기, 치환 또는 비치환된 C6~C40의 아릴포스핀옥사이드기 및 치환 또는 비치환된 C6~C40의 아릴실릴기로 이루어진 군에서 선택되거나, 또는 인접하는 기와 결합하여 축합 고리를 형성할 수 있고, 바람직하게는 각각 독립적으로 수소, 중수소, 치환 또는 비치환된 C6~C40의 아릴기, 치환 또는 비치환된 핵원자수 5 내지 40의 헤테로아릴기 및 치환 또는 비치환된 C6~C40의 아릴아민기로 이루어진 군에서 선택될 수 있다.R 6 to R 9 are the same or different and each independently represents hydrogen, deuterium, halogen, cyano, substituted or unsubstituted C 1 to C 40 alkyl group, substituted or unsubstituted C 2 to C 40 alkenyl group , A substituted or unsubstituted C 2 to C 40 alkynyl group, a substituted or unsubstituted C 6 to C 40 aryl group, a substituted or unsubstituted heteroaryl group having 5 to 40 nucleus atoms, a substituted or unsubstituted A C 6 to C 40 aryloxy group, a substituted or unsubstituted C 1 to C 40 alkyloxy group, a substituted or unsubstituted C 6 to C 40 arylamine group, a substituted or unsubstituted C 3 to C 40 A substituted or unsubstituted C 1 to C 40 alkylsilyl group, a substituted or unsubstituted C 1 to C 40 alkylboron group, a substituted or unsubstituted C 1 to C 40 alkylcarbonyl group, a substituted or unsubstituted heterocycloalkyl group having 3 to 40 nucleus atoms, a substituted or unsubstituted C 1 to C 40 alkylsilyl group, substituted or unsubstituted C 6 ~ C 40 aryl boron group, a substituted or unsubstituted C 6 ~ C 40 aryl phosphine group, a substituted or unsubstituted C 6 ~ C 40 ring An aryl phosphine oxide group and a substituted or unsubstituted C 6 to C 40 arylsilyl group, or may be bonded to an adjacent group to form a condensed ring, and preferably each independently represents hydrogen, deuterium , A substituted or unsubstituted C 6 to C 40 aryl group, a substituted or unsubstituted heteroaryl group having 5 to 40 nucleus atoms, and a substituted or unsubstituted C 6 to C 40 arylamine group .

이때, 상기 R6 내지 R9의 알킬기, 알케닐기, 알키닐기, 아릴기, 헤테로아릴기, 아릴옥시기, 알킬옥시기, 아릴아민기, 시클로알킬기, 헤테로시클로알킬기, 알킬실릴기, 알킬보론기, 아릴보론기, 아릴포스핀기, 아릴포스핀옥사이드기 및 아릴실릴기에 각각 도입되는 하나 이상의 치환기는 각각 독립적으로 중수소, 할로겐, 시아노기, C1~C40의 알킬기, C2~C40의 알케닐기, C2~C40의 알키닐기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴옥시기, C1~C40의 알킬옥시기, C6~C40의 아릴아민기, C3~C40의 시클로알킬기, 핵원자수 3 내지 40의 헤테로시클로알킬기, C1~C40의 알킬실릴기, C1~C40의 알킬보론기, C6~C60의 아릴보론기, C6~C40의 아릴포스핀기, C6~C40의 아릴포스핀옥사이드기 및 C6~C40의 아릴실릴기로 이루어진 군으로부터 선택되고, 다만 상기 치환기가 복수인 경우, 서로 동일하거나 상이할 수 있다.In this case, the alkyl group of the R 6 to R 9, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aryloxy group, an alkyloxy group, an arylamine group, a cycloalkyl group, a heterocycloalkyl group, alkylsilyl group, an alkyl boronic group , an aryl boron group, an aryl phosphine group, aryl phosphine oxide groups and arylsilyl groups or a salt thereof introduced respectively are each independently a heavy hydrogen, a halogen, cyano group, C 1 ~ C 40 alkyl group, C 2 ~ alkenyl of C 40 A C 2 to C 40 alkynyl group, a C 6 to C 40 aryl group, a heteroaryl group having 5 to 40 nuclear atoms, a C 6 to C 40 aryloxy group, a C 1 to C 40 alkyloxy group , A C 6 to C 40 arylamine group, a C 3 to C 40 cycloalkyl group, a heterocycloalkyl group having 3 to 40 nuclear atoms, a C 1 to C 40 alkylsilyl group, a C 1 to C 40 alkylboron group , C 6 ~ C 60 aryl boron group, C 6 ~ C 40 aryl phosphine group, C 6 ~ C 40 aryl phosphine oxide group, and a C 6 ~ C 40 aryl silyl group consisting of Is selected from, but may be a case where the substituent is plural, the same or different from each other.

본 발명에 따른 화학식 1의 화합물에서, 바람직하게는 R1 내지 R9, 및 Ar1 내지 Ar6은 각각 독립적으로 수소, 또는 하기 치환기 S1 내지 S206으로 이루어진 군에서 선택될 수 있는데, 이에 한정되는 것은 아니다. 다만, R1 및 R2 , R2 및 R3, R3 및 R4 중 적어도 하나는 서로 결합하여 상기 화학식 2로 표시되는 축합고리를 형성한다.In the compound of formula (I) according to the present invention, preferably, R 1 to R 9 , and Ar 1 to Ar 6 are each independently selected from the group consisting of hydrogen, or substituents S1 to S206, no. Provided that at least one of R 1 and R 2 , R 2 and R 3 , R 3 and R 4 is bonded to each other to form a condensed ring represented by the general formula (2).

Figure 112012102405784-pat00003
Figure 112012102405784-pat00003

Figure 112012102405784-pat00004
Figure 112012102405784-pat00004

Figure 112012102405784-pat00005
Figure 112012102405784-pat00005

Figure 112012102405784-pat00006
Figure 112012102405784-pat00006

Figure 112012102405784-pat00007
Figure 112012102405784-pat00007

Figure 112012102405784-pat00008
Figure 112012102405784-pat00008

상기 화학식 1의 화합물에서, 상기 Ar1 내지 Ar6은 하기 치환기 A1 내지 A65로 이루어진 군에서 선택되는 것이 더 바람직할 수 있다.In the compound of Formula 1, Ar 1 to Ar 6 may be more preferably selected from the group consisting of Substituents A 1 to A 65 shown below.

Figure 112012102405784-pat00009
Figure 112012102405784-pat00009

Figure 112012102405784-pat00010
Figure 112012102405784-pat00010

Figure 112012102405784-pat00011
Figure 112012102405784-pat00011

Figure 112012102405784-pat00012
Figure 112012102405784-pat00012

Figure 112012102405784-pat00013
Figure 112012102405784-pat00013

Figure 112012102405784-pat00014
Figure 112012102405784-pat00014

본 발명에 따른 화학식 1로 표시되는 화합물의 예로는 하기 화학식 3 내지 화학식 8으로 표시되는 화합물 등이 있는데, 이에 한정되지 않는다.Examples of the compound represented by the formula (1) according to the present invention include compounds represented by the following formulas (3) to (8), but are not limited thereto.

Figure 112012102405784-pat00015
Figure 112012102405784-pat00015

Figure 112012102405784-pat00016
Figure 112012102405784-pat00016

Figure 112012102405784-pat00017
Figure 112012102405784-pat00017

Figure 112012102405784-pat00018
Figure 112012102405784-pat00018

Figure 112012102405784-pat00019
Figure 112012102405784-pat00019

Figure 112012102405784-pat00020
Figure 112012102405784-pat00020

상기 화학식 3 내지 화학식 8 에서,In the above Chemical Formulas 3 to 8,

상기 R1 내지 R9, 및 X1은 각각 상기 화학식 1에서 정의된 바와 같다.R 1 to R 9 , and X 1 are as defined in Formula 1, respectively.

상기 화학식 1로 표시되는 화합물의 대표적인 예로는 하기 화합물들이 있으나, 이에 한정되는 것은 아니다.Representative examples of the compound represented by the formula (1) include, but are not limited to, the following compounds.

Figure 112012102405784-pat00021
Figure 112012102405784-pat00021

Figure 112012102405784-pat00022
Figure 112012102405784-pat00022

Figure 112012102405784-pat00023
Figure 112012102405784-pat00023

Figure 112012102405784-pat00024
Figure 112012102405784-pat00024

Figure 112012102405784-pat00025
Figure 112012102405784-pat00025

Figure 112012102405784-pat00026
Figure 112012102405784-pat00026

Figure 112012102405784-pat00027
Figure 112012102405784-pat00027

Figure 112012102405784-pat00028
Figure 112012102405784-pat00028

Figure 112012102405784-pat00029
Figure 112012102405784-pat00029

Figure 112012102405784-pat00030
Figure 112012102405784-pat00030

Figure 112012102405784-pat00031
Figure 112012102405784-pat00031

Figure 112012102405784-pat00032
Figure 112012102405784-pat00032

Figure 112012102405784-pat00033
Figure 112012102405784-pat00033

Figure 112012102405784-pat00034
Figure 112012102405784-pat00034

Figure 112012102405784-pat00035
Figure 112012102405784-pat00035

Figure 112012102405784-pat00036
Figure 112012102405784-pat00036

Figure 112012102405784-pat00037
Figure 112012102405784-pat00037

Figure 112012102405784-pat00038
Figure 112012102405784-pat00038

Figure 112012102405784-pat00039
Figure 112012102405784-pat00039

Figure 112012102405784-pat00040
Figure 112012102405784-pat00040

Figure 112012102405784-pat00041
Figure 112012102405784-pat00041

Figure 112012102405784-pat00042
Figure 112012102405784-pat00042

Figure 112012102405784-pat00043
Figure 112012102405784-pat00043

Figure 112012102405784-pat00044
Figure 112012102405784-pat00044

Figure 112012102405784-pat00045
Figure 112012102405784-pat00045

본 발명에서 사용된 "비치환된 알킬"은 탄소수 1 내지 40의 직쇄 또는 측쇄의 포화 탄화수소에서 유래되는 1가의 치환기이며, 이의 예로는 메틸, 에틸, 프로필, 이소부틸, sec-부틸, 펜틸, iso-아밀, 헥실 등을 포함한다. As used herein, "unsubstituted alkyl" is a monovalent substituent derived from a straight or branched saturated hydrocarbon having 1 to 40 carbon atoms, and examples thereof include methyl, ethyl, propyl, isobutyl, sec-butyl, pentyl, iso -Amyl, hexyl, and the like.

"비치환된 알케닐(alkenyl)"은 탄소-탄소 이중 결합을 1개 이상 가진, 탄소수 2 내지 40의 직쇄 또는 측쇄의 불포화 탄화수소에서 유래되는 1가의 치환기이며, 이의 예로는 비닐(vinyl), 알릴(allyl), 이소프로펜일(isopropenyl), 2-부텐일(2-butenyl) 등이 있으며, 이에 한정되는 것은 아니다. "Unsubstituted alkenyl" is a monovalent substituent derived from a straight or branched unsaturated hydrocarbon having 2 to 40 carbon atoms and having at least one carbon-carbon double bond. Examples thereof include vinyl, allyl, but are not limited to, allyl, isopropenyl, 2-butenyl, and the like.

"비치환된 알키닐(alkynyl)"은 탄소-탄소 삼중 결합을 1개 이상 가진, 탄소수 2 내지 40의 직쇄 또는 측쇄의 불포화 탄화수소에서 유래되는 1가의 치환기이며, 이의 예로는 에타인일(ethynyl), 2-프로파인일(2-propynyl) 등이 있는데, 이에 제한되는 것은 아니다."Unsubstituted alkynyl" is a monovalent substituent derived from a straight or branched chain unsaturated hydrocarbon having 2 to 40 carbon atoms and having at least one carbon-carbon triple bond. Examples thereof include ethynyl, , 2-propynyl, and the like, but are not limited thereto.

"비치환된 아릴"은 단독 고리 또는 2 이상의 고리가 조합된, 탄소수 6 내지 60의 방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 2 이상의 고리가 서로 단순 부착(pendant)되거나 축합된(fused) 형태로 부착될 수 있다. 아릴의 예로는 페닐, 나프틸, 페난트릴, 안트릴 등이 포함되며 이에 한정되는 것은 아니다."Unsubstituted aryl" means a monovalent substituent derived from an aromatic hydrocarbon having 6 to 60 carbon atoms, either alone or in combination with at least two rings. Two or more rings may be attached to each other in a pendant or fused form to each other. Examples of aryl include, but are not limited to, phenyl, naphthyl, phenanthryl, anthryl, and the like.

"비치환된 헤테로아릴"은 핵원자수 5 내지 40의 모노헤테로사이클릭 또는 폴리헤테로사이클릭 방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 고리 중 하나 이상의 탄소, 바람직하게는 1 내지 3개의 탄소가 N, O, S 또는 Se와 같은 헤테로원자로 치환된다. 2 이상의 고리가 서로 단순 부착(pendant)되거나 축합된(fused) 형태로 부착될 수 있고, 나아가 아릴기와의 축합된 형태도 포함하는 것으로 해석한다. 헤테로아릴의 예로는 피리딜, 피라지닐, 피리미디닐, 피리다지닐, 트리아지닐과 같은 6-원 모노사이클릭 고리; 페녹사티에닐(phenoxathienyl), 인돌리지닐(indolizinyl), 인돌릴(indolyl), 퓨리닐(purinyl), 퀴놀릴(quinolyl), 벤조티아졸(benzothiazole), 카바졸릴(carbazolyl)과 같은 폴리사이클릭 고리를 포함하고, 2-퓨라닐, N-이미다졸릴, 2-이속사졸릴, 2-피리디닐, 2-피리미디닐 등도 포함하는 것으로 해석한다."Unsubstituted heteroaryl" means a monovalent substituent derived from a monoheterocyclic or polyheterocyclic aromatic hydrocarbon having 5 to 40 nuclear atoms. One or more carbons, preferably one to three carbons, of the ring are substituted with a heteroatom such as N, O, S or Se. It is interpreted that two or more rings may be attached to each other in a pendant or fused form to each other and further include a condensed form with an aryl group. Examples of heteroaryl include 6-membered monocyclic rings such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and triazinyl; Such as phenoxathienyl, indolizinyl, indolyl, purinyl, quinolyl, benzothiazole, carbazolyl, and the like. Includes rings and is also meant to include 2-furanyl, N-imidazolyl, 2-isoxazolyl, 2-pyridinyl, 2-pyrimidinyl and the like.

"비치환된 아릴옥시"는 RO-로 표시되는 1가의 치환기로서, 상기 R은 탄소수 5 내지 60의 아릴이다. 아릴옥시의 예로는 페닐옥시, 나프틸옥시, 디페닐옥시 등이 있다."Unsubstituted aryloxy" is a monovalent substituent represented by RO-, wherein R is aryl having 5 to 60 carbon atoms. Examples of aryloxy include phenyloxy, naphthyloxy, diphenyloxy, and the like.

"비치환된 알킬옥시"는 R'O-로 표시되는 1가의 치환기로서, 상기 R'는 1 내지 40개의 알킬을 의미하며, 직쇄(linear), 측쇄(branched) 또는 사이클릭(cyclic) 구조를 포함하는 것으로 해석한다. 알킬옥시의 예로는 메톡시, 에톡시, n-프로폭시, 1-프로폭시, t-부톡시, n-부톡시, 펜톡시 등이 포함될 수 있으며 이에 한정되지는 않는다. "Unsubstituted alkyloxy" means a monovalent substituent group represented by R'O-, wherein R 'represents an alkyl having 1 to 40 carbon atoms, and may have a linear, branched or cyclic structure . Examples of alkyloxy include, but are not limited to, methoxy, ethoxy, n-propoxy, 1-propoxy, t-butoxy, n-butoxy, pentoxy and the like.

"비치환된 아릴아민"은 탄소수 6 내지 60의 아릴로 치환된 아민을 의미한다."Unsubstituted arylamine" means an amine substituted with aryl having 6 to 60 carbon atoms.

"비치환된 시클로알킬"은 탄소수 3 내지 40의 모노사이클릭 또는 폴리사이클릭 비-방향족 탄화수소로부터 유래된 1가의 치환기를 의미한다. 이러한 사이클로알킬의 예로는 사이클로프로필, 사이클로펜틸, 사이클로헥실, 놀보닐(norbornyl), 아다만틴(adamantine)등이 포함되지만 이에 한정되는 것은 아니다. "Unsubstituted cycloalkyl" means a monovalent substituent derived from a monocyclic or polycyclic non-aromatic hydrocarbon having from 3 to 40 carbon atoms. Examples of such cycloalkyls include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, norbornyl, adamantine, and the like.

"비치환된 헤테로시클로알킬"은 핵원자수 3 내지 40의 비-방향족 탄화수소로부터 유래된 1가의 치환기를 의미하며, 고리 중 하나 이상의 탄소, 바람직하게는 1 내지 3개의 탄소가 N, O 또는 S와 같은 헤테로 원자로 치환된다. 이의 비-제한적인 예로는 모르폴린, 피페라진 등이 있다."Unsubstituted heterocycloalkyl" means a monovalent substituent derived from a non-aromatic hydrocarbon having 3 to 40 nuclear atoms, wherein at least one of the carbons, preferably one to three carbons, is replaced by N, O, or S Lt; / RTI > Non-limiting examples thereof include morpholine, piperazine, and the like.

"알킬실릴"은 탄소수 1 내지 40의 알킬로 치환된 실릴이고, "아릴실릴"은 탄소수 5 내지 40의 아릴로 치환된 실릴을 의미한다."Alkylsilyl" is silyl substituted with alkyl having 1 to 40 carbon atoms, and "arylsilyl" means silyl substituted with aryl having 5 to 40 carbon atoms.

"축합(fused) 고리"는 축합 지방족 고리, 축합 방향족 고리, 축합 헤테로지방족 고리, 축합 헤테로방향족 고리 또는 이들의 조합된 형태를 의미한다."Fused ring" means a fused aliphatic ring, a fused aromatic ring, a fused heteroaliphatic ring, a fused heteroaromatic ring, or a combination thereof.

본 발명의 화학식 1의 화합물은 일반적인 합성방법에 따라 합성될 수 있다(Chem. Rev., 60:313 (1960); J. Chem. SOC. 4482 (1955); Chem. Rev. 95: 2457 (1995) 등 참조). 본 발명의 화합물에 대한 상세한 합성 과정은 후술하는 합성예에서 구체적으로 기술하도록 한다.
The compounds of formula 1 of the present invention can be synthesized according to the general synthetic methods ( Chem. Rev. , 60 : 313 (1960); J. Chem. SOC . 4482 (1955); Chem. Rev. 95: 2457 (1995 ). Detailed synthesis of the compound of the present invention will be described in detail in Synthesis Examples to be described later.

한편, 본 발명은 전술한 화학식 1로 표시되는 화합물, 바람직하게는 화학식 3로 표시되는 화합물 내지 화학식 8로 표시되는 화합물을 포함하는 유기 전계 발광 소자를 제공한다.Meanwhile, the present invention provides an organic electroluminescent device comprising the compound represented by the above-mentioned formula (1), preferably the compound represented by the formula (3) to the compound represented by the formula (8).

구체적으로, 본 발명은 양극(anode), 음극(cathode), 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하는 유기 전계 발광 소자로서, 상기 1층 이상의 유기물층 중 적어도 하나는 상기 화학식 1로 표시되는 화합물, 바람직하게는 화학식 3로 표시되는 화합물 내지 화학식 8로 표시되는 화합물을 포함한다. 이때, 상기 화합물은 단독으로 또는 2 이상이 혼합되어 사용될 수 있다.Specifically, the present invention is an organic electroluminescent device comprising an anode, a cathode, and one or more organic layers sandwiched between the anode and the cathode, wherein at least one of the one or more organic layers includes The compound represented by the above formula (1), preferably the compound represented by the formula (3) to the compound represented by the formula (8). At this time, the compounds may be used singly or in combination of two or more.

상기 1층 이상의 유기물층은 정공주입층, 정공수송층, 발광층, 전자수송층 및 전자주입층 중 어느 하나 이상일 수 있고, 이 중에서 적어도 하나의 유기물층이 상기 화학식 1로 표시되는 화합물을 포함할 수 있다. 바람직하게는 상기 화합물 1의 화합물을 포함하는 유기물층은 발광층일 수 있다.The one or more organic layers may be at least one of a hole injecting layer, a hole transporting layer, a light emitting layer, an electron transporting layer, and an electron injecting layer, and at least one organic layer may include a compound represented by Formula 1. Preferably, the organic compound layer containing the compound of Compound 1 may be an emissive layer.

본 발명의 일례에 따르면, 유기 전계 발광 소자의 발광층은 호스트 재료를 포함할 수 있는데, 이때 호스트 재료로서 상기 화학식 1의 화합물을 포함할 수 있다. 이와 같이, 상기 화학식 1의 화합물을 유기 전계 발광 소자의 발광층 재료, 바람직하게는 청색, 녹색, 적색의 인광 호스트로 포함할 경우, 발광층에서 정공과 전자의 결합력이 높아지기 때문에, 유기 전계 발광 소자의 효율(발광효율 및 전력효율), 수명, 휘도 및 구동전압 등이 향상될 수 있다.According to an embodiment of the present invention, the light emitting layer of the organic electroluminescent device may include a host material, and the host material may include the compound of the above formula (1). Thus, when the compound of Formula 1 is incorporated into a light emitting layer material of an organic electroluminescent device, preferably a blue, green, or red phosphorescent host, the bonding strength between holes and electrons in the light emitting layer is increased. (Luminous efficiency and power efficiency), lifetime, luminance, driving voltage, and the like can be improved.

전술한 본 발명에 따른 유기 전계 발광 소자의 구조는 특별히 한정되지 않으며, 예컨대 기판, 양극, 정공주입층, 정공수송층, 발광층, 전자수송층 및 음극이 순차적으로 적층된 구조일 수 있다. 이때, 상기 정공주입층, 정공수송층, 발광층, 전자수송층 및 전자주입층 중 하나 이상은 상기 화학식 1로 표시되는 화합물을 포함할 수 있고, 바람직하게는 발광층이 상기 화학식 1로 표시되는 화합물을 포함할 수 있다. 특히, 본 발명의 화합물은 발광층의 인광 호스트로 이용될 수 있다. 상기 전자수송층 위에는 전자주입층이 추가로 적층될 수 있다. The structure of the organic electroluminescent device according to the present invention is not particularly limited and may be a structure in which a substrate, an anode, a hole injecting layer, a hole transporting layer, a light emitting layer, an electron transporting layer, and a cathode are sequentially stacked. At least one of the hole injecting layer, the hole transporting layer, the light emitting layer, the electron transporting layer, and the electron injecting layer may include a compound represented by Formula 1, and preferably, the emitting layer includes a compound represented by Formula 1 . In particular, the compound of the present invention can be used as a phosphorescent host of a light emitting layer. An electron injection layer may be further stacked on the electron transport layer.

또한, 본 발명에 따른 유기 전계 발광 소자의 구조는 양극, 1층 이상의 유기물층 및 음극이 순차적으로 적층될 뿐만 아니라, 전극과 유기물층 계면에 절연층 또는 접착층이 삽입된 구조일 수 있다.In addition, the structure of the organic electroluminescent device according to the present invention may be a structure in which an anode, one or more organic layers and an anode are sequentially laminated, and an insulating layer or an adhesive layer is inserted into the interface between the electrode and the organic layer.

본 발명에 따른 유기 전계 발광 소자는 상기 유기물층 중 1층 이상(예컨대, 발광층)이 상기 화학식 1로 표시되는 화합물을 포함하도록 형성하는 것을 제외하고는, 당 기술 분야에 알려져 있는 재료 및 방법을 이용하여 다른 유기물층 및 전극을 형성하여 제조될 수 있다.The organic electroluminescent device according to the present invention may be formed by using materials and methods known in the art, except that at least one layer (for example, a light emitting layer) of the organic material layer includes the compound represented by Formula 1 Other organic material layers and electrodes.

상기 유기물층은 진공 증착법이나 용액 도포법에 의하여 형성될 수 있다. 상기 용액 도포법의 예로는 스핀 코팅, 딥코팅, 닥터 블레이딩, 잉크젯 프린팅 또는 열 전사법 등이 있으나, 이들에 한정되지 않는다.The organic material layer may be formed by a vacuum deposition method or a solution coating method. Examples of the solution coating method include, but are not limited to, spin coating, dip coating, doctor blading, inkjet printing, or thermal transfer.

본 발명에서 사용 가능한 기판으로는 특별히 한정되지 않으며, 실리콘 웨이퍼, 석영, 유리판, 금속판, 플라스틱 필름 및 시트 등이 사용될 수 있다.The substrate usable in the present invention is not particularly limited, and a silicon wafer, quartz, a glass plate, a metal plate, a plastic film and a sheet can be used.

또, 양극 물질로는 바나듐, 크롬, 구리, 아연, 금과 같은 금속 또는 이들의 합금; 아연산화물, 인듐산화물, 인듐 주석 산화물(ITO), 인듐 아연 산화물(IZO)과 같은 금속 산화물; ZnO:Al 또는 SnO2:Sb와 같은 금속과 산화물의 조합; 폴리티오펜, 폴리(3-메틸티오펜), 폴리[3,4-(에틸렌-1,2-디옥시)티오펜](PEDT), 폴리피롤 또는 폴리아닐린과 같은 전도성 고분자; 및 카본블랙 등이 있는데, 이에 한정되지 않는다.Examples of the positive electrode material include metals such as vanadium, chromium, copper, zinc, and gold, or alloys thereof; Metal oxides such as zinc oxide, indium oxide, indium tin oxide (ITO), and indium zinc oxide (IZO); ZnO: Al or SnO 2: a combination of a metal and an oxide such as Sb; Conductive polymers such as polythiophene, poly (3-methylthiophene), poly [3,4- (ethylene-1,2-dioxy) thiophene] (PEDT), polypyrrole or polyaniline; And carbon black, but are not limited thereto.

또, 음극 물질로는 마그네슘, 칼슘, 나트륨, 칼륨, 타이타늄, 인듐, 이트륨, 리튬, 가돌리늄, 알루미늄, 은, 주석, 또는 납과 같은 금속 또는 이들의 합금; 및 LiF/Al 또는 LiO2/Al과 같은 다층 구조 물질 등이 있는데, 이에 한정되지 않는다.
The negative electrode material may be a metal such as magnesium, calcium, sodium, potassium, titanium, indium, yttrium, lithium, gadolinium, aluminum, silver, tin or lead or an alloy thereof; And multi-layer structure materials such as LiF / Al or LiO 2 / Al, but are not limited thereto.

이하 본 발명을 실시예를 통하여 상세히 설명하면 다음과 같다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited by the following examples.

[준비예 1] 화합물 IC-1 및 IC-2의 합성[Preparation Example 1] Synthesis of compound IC-1 and IC-2

<단계 1> 5-(4,4,5,5-&Lt; Step 1 > 5- (4,4,5,5- tetramethyltetramethyl -1,3,2--1,3,2- dioxaborolandioxaborolan -2--2- ylyl )-1H-) -1H- indazole 의indazole 합성 synthesis

Figure 112012102405784-pat00046
Figure 112012102405784-pat00046

질소 기류 하에서 5-bromo-1H-indazole (25.22 g, 0.128 mol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (48.58 g, 0.191 mol), Pd(dppf)Cl2 (5.2 g, 5 mol), KOAc (37.55 g, 0.383 mol) 및 1,4-dioxane (500 ml)를 혼합한 다음, 130℃에서 12시간 동안 교반하였다.(25.22 g, 0.128 mol), 4,4,4 ', 4', 5,5,5 ', 5'-octamethyl-2,2'-bi (1,3 Dioxaborolane (48.58 g, 0.191 mol), Pd (dppf) Cl 2 (5.2 g, 5 mol), KOAc (37.55 g, 0.383 mol) and 1,4- And the mixture was stirred at 130 DEG C for 12 hours.

반응이 종결된 후 에틸아세테이트로 추출한 다음, MgSO4로 수분을 제거하고, 컬럼크로마토그래피 (Hexane:EA = 10:1 (v/v))로 정제하여 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (22.49 g, 수율: 72%)을 얻었다. Extracted with ethyl acetate. After the reaction was terminated, and then, dried with MgSO 4 and purified by column chromatography (Hexane: EA = 10: 1 (v / v)) 5- (4,4,5,5- to give tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole (22.49 g, yield: 72%).

1H-NMR: δ 1.24 (s, 12H), 7.60 (d, 1H), 8.15 (m, 2H), 8.34 (d, 1H), 12.34 (s, 1H) 1 H-NMR: δ 1.24 ( s, 12H), 7.60 (d, 1H), 8.15 (m, 2H), 8.34 (d, 1H), 12.34 (s, 1H)

<단계 2> 5-(2-<Step 2> Synthesis of 5- (2- nitrophenylnitrophenyl )-1H-) -1H- indazoleindazole 의 합성Synthesis of

Figure 112012102405784-pat00047
Figure 112012102405784-pat00047

질소 기류 하에서 1-bromo-2-nitrobenzene (15.23 g, 75.41 mmol)과 상기 준비예 1의 <단계 1>에서 얻은 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (22.09 g, 90.49 mmol), NaOH (9.05 g, 226.24 mmol) 및 THF/H2O(400 ml/200 ml)를 혼합한 다음, 40℃에서 Pd(PPh3)4(4.36 g, 5 mol%)를 넣고 80℃에서 12시간 동안 교반하였다. 1-bromo-2-nitrobenzene (15.23 g, 75.41 mmol) and 5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl) -1H-indazole ( 22.09 g, 90.49 mmol), NaOH (9.05 g, 226.24 mmol) and THF / H 2 O (400 ml / 200 ml) , and then, Pd (PPh 3 at 40 ℃ mixing) 4 (4.36 g, 5 mol%) was added thereto, and the mixture was stirred at 80 ° C for 12 hours.

반응 종결 후 메틸렌클로라이드로 추출한 다음, MgSO4를 넣고 여과하였다. 얻어진 유기층에서 용매를 제거한 후 컬럼 크로마토그래피 (Hexane:EA = 3:1 (v/v))로 정제하여 5-(2-nitrophenyl)-1H-indazole (13.64 g, 수율: 63%)을 얻었다. After completion of the reaction, the reaction mixture was extracted with methylene chloride, and then MgSO 4 was added thereto. The solvent was removed from the obtained organic layer and then purified by column chromatography (Hexane: EA = 3: 1 (v / v)) to obtain 5- (2-nitrophenyl) -1H-indazole (13.64 g, yield 63%).

1H-NMR: δ 7.64 (m, 2H), 7.90 (m, 1H), 8.05 (m, 3H), 8.21 (s, 1H), 8.38(d, 1H), 12.24(s, 1H) 1 H-NMR: 8 7.64 (m, 2H), 7.90 (m, IH), 8.05 (m, 3H), 8.21

<단계 3> 5-(2-nitrophenyl)-1-phenyl-1H-indazole의 합성<Step 3> Synthesis of 5- (2-nitrophenyl) -1-phenyl-1H-indazole

Figure 112012102405784-pat00048
Figure 112012102405784-pat00048

질소 기류 하에서 상기 준비예 1의 <단계 2>에서 얻은 5-(2-nitrophenyl)-1H-indazole (11.04 g, 46.17 mmol), iodobenzene (14.13 g, 69.26 mmol), Cu powder (0.29 g, 4.62 mmol), K2CO3 (6.38 g, 46.17 mmol), Na2SO4 (6.56 g, 46.17 mmol), nitrobenzene (200 ml)를 혼합한 다음, 190℃에서 12시간 동안 교반하였다. (2-nitrophenyl) -1H-indazole (11.04 g, 46.17 mmol), iodobenzene (14.13 g, 69.26 mmol) and Cu powder (0.29 g, 4.62 mmol) obtained in Step 2 of Preparation Example 1 ), K 2 CO 3 (6.38 g, 46.17 mmol), Na 2 SO 4 (6.56 g, 46.17 mmol) and nitrobenzene (200 ml) were mixed and stirred at 190 ° C for 12 hours.

반응 종결 후 nitrobenzene을 제거한 다음, 메틸렌클로라이드로 유기층을 분리하여 MgSO4를 사용하여 물을 제거하였다. 물이 제거된 유기층에서 용매를 제거한 후 컬럼 크로마토그래피 (Hexane:MC = 3:1 (v/v))로 정제하여 5-(2-nitrophenyl)-1-phenyl-1H-indazole (10.34 g, 수율: 71%)을 얻었다. After completion of the reaction, nitrobenzene was removed, and the organic layer was separated with methylene chloride, and water was removed using MgSO 4 . After removing the solvent from the organic layer from which water had been removed, the residue was purified by column chromatography (Hexane: MC = 3: 1 (v / v)) to obtain 5- (2-nitrophenyl) -1- : 71%).

1H-NMR: δ 7.48 (t, 1H), 7.62 (m, 6H), 7.90 (m, 1H), 8.05 (m, 3H), 8.37 (m, 2H) 1 H-NMR: δ 7.48 ( t, 1H), 7.62 (m, 6H), 7.90 (m, 1H), 8.05 (m, 3H), 8.37 (m, 2H)

<단계 4> 화합물 IC-1 및 IC-2의 합성<Step 4> Synthesis of Compound IC-1 and IC-2

Figure 112012102405784-pat00049
Figure 112012102405784-pat00049

질소 기류 하에서 상기 준비예 1의 <단계 3>에서 얻은 5-(2-nitrophenyl)-1-phenyl-1H-indazole (5.01 g, 15.91 mmol), triphenylphosphine (10.43 g, 39.77 mmol) 및 1,2-dichlorobenzene (50 ml)를 혼합한 다음, 12시간 동안 교반하였다.Phenyl-1H-indazole (5.01 g, 15.91 mmol), triphenylphosphine (10.43 g, 39.77 mmol) obtained in Step 3 of Preparation Example 1 and 1,2- dichlorobenzene (50 ml) were mixed and stirred for 12 hours.

반응 종료 후 1,2-dichlorobenzene를 제거하고 디클로로메탄으로 추출하였다. 얻어진 유기층에 대해 MgSO4로 물을 제거하고, 컬럼크로마토그래피 (Hexane:MC=3:1 (v/v))로 정제하여 화합물 IC-1 (2.39 g, 수율: 53%) 및 화합물 IC-2를 얻었다. After completion of the reaction, 1,2-dichlorobenzene was removed and extracted with dichloromethane. The obtained organic layer was washed with MgSO 4 and purified by column chromatography (Hexane: MC = 3: 1 (v / v)) to obtain a compound IC-1 (2.39 g, yield: 53% .

화합물 IC-1의 1H-NMR: δ 7.29 (t, 1H), 7.45 (m, 3H), 7.60 (m, 5H), 8.12 (d, 1H), 8.33 (d, 2H), 10.09 (s, 1H)Compound IC-1 1 of H-NMR: δ 7.29 (t , 1H), 7.45 (m, 3H), 7.60 (m, 5H), 8.12 (d, 1H), 8.33 (d, 2H), 10.09 (s, 1H)

화합물 IC-2의 1H-NMR: δ 7.29 (t, 1H), 7.47 (m, 2H), 7.60 (m, 6H), 7.85 (s, 1H), 8.12 (d, 1H), 8.37 (s, 1H), 10.21 (s, 1H)
Compound IC-2 1 H-NMR of: δ 7.29 (t, 1H) , 7.47 (m, 2H), 7.60 (m, 6H), 7.85 (s, 1H), 8.12 (d, 1H), 8.37 (s, 1H), 10.21 (s, 1 H)

[준비예 2] 화합물 IC-3 및 IC-4의 합성[Preparation Example 2] Synthesis of compound IC-3 and IC-4

<단계 1> 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole의 합성<Step 1> Synthesis of 6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole

Figure 112012102405784-pat00050
Figure 112012102405784-pat00050

준비예 1의 <단계 1>에서 사용된 5-bromo-1H-indazole 대신 6-bromo-1H-indazole (25.22 g, 0.128 mol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 1>과 동일한 과정을 수행하여 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole을 얻었다.Step 1 of Preparation Example 1 was repeated except that 6-bromo-1H-indazole (25.22 g, 0.128 mol) was used instead of 5-bromo-1H-indazole used in Step 1 of Preparation Example 1, To obtain 6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole.

1H-NMR: δ 1.25 (s, 12H), 7.48 (d, 1H), 7.89 (m, 2H), 8.21 (s, 1H), 12.15 (s, 1H) 1 H-NMR:? 1.25 (s, 12H), 7.48 (d, IH), 7.89 (m, 2H), 8.21

<단계 2> 6-(2-nitrophenyl)-1H-indazole의 합성<Step 2> Synthesis of 6- (2-nitrophenyl) -1H-indazole

Figure 112012102405784-pat00051
Figure 112012102405784-pat00051

준비예 1의 <단계 2>에서 사용된 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 대신 상기 준비예 2의 <단계 1>에서 얻은 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (22.09 g, 90.49 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 2>과 동일한 과정을 수행하여 6-(2-nitrophenyl)-1H-indazole을 얻었다.Step 1 of Preparation Example 2 was used instead of 5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole used in Step 2 of Preparation Example 1, Except that the 6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole (22.09 g, 90.49 mmol) (2-nitrophenyl) -1H-indazole was obtained in the same manner as in < Step 2 >.

1H-NMR: δ 7.49 (d, 1H), 7.67 (t, 1H), 7.85 (s, 1H), 7.94 (m, 2H), 8.03 (m, 2H), 8.20 (s, 1H), 12.2 (s, 1H) 1 H-NMR: δ 7.49 ( d, 1H), 7.67 (t, 1H), 7.85 (s, 1H), 7.94 (m, 2H), 8.03 (m, 2H), 8.20 (s, 1H), 12.2 ( s, 1 H)

<단계 3> 6-(2-nitrophenyl)-1-phenyl-1H-indazole의 합성<Step 3> Synthesis of 6- (2-nitrophenyl) -1-phenyl-1H-indazole

Figure 112012102405784-pat00052
Figure 112012102405784-pat00052

준비예 1의 <단계 1>에서 사용된 5-(2-nitrophenyl)-1H-indazole 대신 상기 준비예 2의 <단계 2>에서 얻은 6-(2-nitrophenyl)-1H-indazole (11.04 g, 46.17 mmol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 3>과 동일한 과정을 수행하여 6-(2-nitrophenyl)-1-phenyl-1H-indole을 얻었다.(2-nitrophenyl) -1H-indazole (11.04 g, 46.17 mmol) obtained in Step 2 of Preparation Example 2 was used in place of 5- (2-nitrophenyl) -1H-indazole used in Step 1 of Preparation Example 1 (2-nitrophenyl) -1-phenyl-1H-indole was obtained by following the procedure of <Step 3> of Preparation Example 1,

1H-NMR: δ 7.47 (m, 2H), 7.62 (m, 5H), 7.83 (s, 1H), 7.95 (m, 2H), 8.02 (m, 2H), 8.39 (s, 1H) 1 H-NMR: δ 7.47 ( m, 2H), 7.62 (m, 5H), 7.83 (s, 1H), 7.95 (m, 2H), 8.02 (m, 2H), 8.39 (s, 1H)

<단계 4> 화합물 IC-3 및 IC-4의 합성<Step 4> Synthesis of Compound IC-3 and IC-4

Figure 112012102405784-pat00053
Figure 112012102405784-pat00053

준비예 1의 <단계 4>에서 사용된 5-(2-nitrophenyl)-1-phenyl-1H-indazole 대신 상기 준비예 2의 <단계 3>에서 얻은 6-(2-nitrophenyl)-1-phenyl-1H-indazole (5.01 g, 15.91 mmol)를 사용하는 것을 제외하고는 상기 준비예 1의 <단계 4>과 동일한 과정을 수행하여 화합물 IC-3 및 IC-4를 얻었다.(2-nitrophenyl) -1-phenyl-1H-indazole obtained in Step 3 of Preparation Example 2 was used instead of 5- (2-nitrophenyl) Compound IC-3 and IC-4 were obtained by following the procedure of <Step 4> of Preparation Example 1, except that 1H-indazole (5.01 g, 15.91 mmol) was used.

화합물 IC-3의 1H-NMR: δ 7.27 (m, 2H), 7.45 (t, 1H), 7.54 (m, 6H), 7.95 (d, 1H), 8.12 (d, 1H), 8.37 (s, 1H), 10.53 (s, 1H)Compound IC-3 1 H-NMR of: δ 7.27 (m, 2H) , 7.45 (t, 1H), 7.54 (m, 6H), 7.95 (d, 1H), 8.12 (d, 1H), 8.37 (s, 1H), 10.53 (s, 1 H)

화합물 IC-4의 1H-NMR: δ 7.29 (t, 1H), 7.45 (t, 1H), 7.50 (m, 1H), 7.58 (m, 6H), 7.88 (s, 1H), 8.11 (d, 1H), 8.33 (s, 1H), 10.64 (s, 1H)
Compound IC-4 1 H-NMR of: δ 7.29 (t, 1H) , 7.45 (t, 1H), 7.50 (m, 1H), 7.58 (m, 6H), 7.88 (s, 1H), 8.11 (d, 1H), 8.33 (s, 1 H), 10.64 (s, 1 H)

[준비예 3] 화합물 IC-5의 합성[Preparation Example 3] Synthesis of Compound IC-5

<단계 1> 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole의 합성<Step 1> Synthesis of 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole

Figure 112012102405784-pat00054
Figure 112012102405784-pat00054

준비예 1의 <단계 1>에서 사용된 5-bromo-1H-indazole 대신 4-bromo-1H-indazole (25.22 g, 0.128 mol)를 사용하는 것을 제외하고는, 상기 준비예 1의 <단계 1>과 동일한 과정을 수행하여 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole을 얻었다.Step 1 of Preparation Example 1 was repeated except that 4-bromo-1H-indazole (25.22 g, 0.128 mol) was used instead of 5-bromo-1H-indazole used in Step 1 of Preparation Example 1, 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole was obtained.

1H NMR: δ 1.26 (s, 12H), 7.43 (d, 1H), 7.66 (t, 1H), 8.28 (m, 2H), 12.23 (s, 1H) 1 H NMR:? 1.26 (s, 12H), 7.43 (d, IH), 7.66

<단계 2> 4-(2-nitrophenyl)-1H-indazole의 합성<Step 2> Synthesis of 4- (2-nitrophenyl) -1H-indazole

Figure 112012102405784-pat00055
Figure 112012102405784-pat00055

준비예 1의 <단계 2>에서 사용된 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 대신 상기 준비예 3의 <단계 1>에서 얻은 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (22.09 g, 90.49 mmol)을 사용하는 것을 제외하고는 상기 준비예 1의 <단계 2>와 동일한 과정을 수행하여 4-(2-nitrophenyl)-1H-indazole을 얻었다.Step 1 of Preparation Example 3 was used instead of 5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole used in <Step 2> Except that 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole (22.09 g, 90.49 mmol) The same procedure as in <Step 2> was conducted to obtain 4- (2-nitrophenyl) -1H-indazole.

1H NMR: δ 7.49 (d, 1H), 7.68 (m, 2H), 7.90 (t, 1H), 8.01 (m, 2H), 8.24 (m, 2H), 12.39 (s, 1H) 1 H NMR: δ 7.49 (d , 1H), 7.68 (m, 2H), 7.90 (t, 1H), 8.01 (m, 2H), 8.24 (m, 2H), 12.39 (s, 1H)

<단계 3> 4-(2-nitrophenyl)-1-phenyl-1H-indazole의 합성<Step 3> Synthesis of 4- (2-nitrophenyl) -1-phenyl-1H-indazole

Figure 112012102405784-pat00056
Figure 112012102405784-pat00056

준비예 1의 <단계 3>에서 사용된 5-(2-nitrophenyl)-1H-indazole 대신 상기 준비예 3의 <단계 2>에서 얻은 4-(2-nitrophenyl)-1H-indazole (11.04 g, 46.17 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 3>과 동일한 과정을 수행하여 4-(2-nitrophenyl)-1-phenyl-1H-indazole을 얻었다.(2-nitrophenyl) -1H-indazole (11.04 g, 46.17 g) obtained in Step 2 of Preparation Example 3 was used in place of 5- (2-nitrophenyl) -1H-indazole used in Step 3 of Preparation Example 1 (2-nitrophenyl) -1-phenyl-1H-indazole was obtained by following the procedure of <Step 3> of Preparation Example 1,

1H NMR: δ 7.47 (m, 2H), 7.64 (m, 6H), 7.90 (t, 1H), 8.00 (m, 2H), 8.31 (m, 2H) 1 H NMR: δ 7.47 (m , 2H), 7.64 (m, 6H), 7.90 (t, 1H), 8.00 (m, 2H), 8.31 (m, 2H)

<단계 4> 화합물 &Lt; Step 4 > ICIC -5의 합성Synthesis of -5

Figure 112012102405784-pat00057
Figure 112012102405784-pat00057

준비예 1의 <단계 4>에서 사용된 5-(2-nitrophenyl)-1-phenyl-1H-indazole 대신 상기 준비예 3의 <단계 3>에서 얻은 4-(2-nitrophenyl)-1-phenyl-1H-indazole (5.01 g, 15.91 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 4>와 동일한 과정을 수행하여 화합물 IC-5을 얻었다.(2-nitrophenyl) -1-phenyl-1H-indazole obtained in Step 3 of Preparation Example 3 was used instead of 5- (2-nitrophenyl) 1H-indazole (5.01 g, 15.91 mmol) was used in the same manner as in <Step 4> of Preparation Example 1 to obtain a compound IC-5.

1H NMR: δ 7.30 (t, 1H), 7.52 (m, 7H), 8.08 (m, 2H), 8.35 (m, 2H), 10.21 (s, 1H)
1 H NMR: δ 7.30 (t , 1H), 7.52 (m, 7H), 8.08 (m, 2H), 8.35 (m, 2H), 10.21 (s, 1H)

[준비예 4] 화합물 IC-6의 합성[Preparation Example 4] Synthesis of Compound IC-6

<단계 1> 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole의 합성<Step 1> Synthesis of 7- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole

Figure 112012102405784-pat00058
Figure 112012102405784-pat00058

준비예 1의 <단계 1>에서 사용된 5-bromo-1H-indazole 대신 7-bromo-1H-indazole (25.22 g, 0.128 mol)를 사용하는 것을 제외하고는, 준비예 1의 <단계 1>과 동일한 과정을 수행하여 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole을 얻었다.Step 1> of Preparation Example 1 was repeated except that 7-bromo-1H-indazole (25.22 g, 0.128 mol) was used instead of 5-bromo-1H-indazole used in Step 1 of Preparation Example 1 The same procedure was followed to obtain 7- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole.

1H NMR: δ 1.25 (s, 12H), 7.44 (t, 1H), 7.62 (d, 1H), 7.95 (d, 1H), 8.36 (s, 1H), 12.51 (s, 1H) 1 H NMR: 8 1.25 (s, 12H), 7.44 (s, 1H), 7.62 (d,

<단계 2> 7-(2-nitrophenyl)-1H-indazole의 합성<Step 2> Synthesis of 7- (2-nitrophenyl) -1H-indazole

Figure 112012102405784-pat00059
Figure 112012102405784-pat00059

준비예 1의 <단계 2>에서 사용된 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 대신 상기 준비예 4의 <단계 1>에서 얻은 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (22.09 g, 90.49 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 2>와 동일한 과정을 수행하여 7-(2-nitrophenyl)-1H-indazole을 얻었다.Step 1 of Preparation Example 4 was used instead of 5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole used in <Step 2> (22.09 g, 90.49 mmol) obtained in PREPARATION EXAMPLE 1 was used instead of 7- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) The procedure of Step 2 was repeated to obtain 7- (2-nitrophenyl) -1H-indazole.

1H NMR: δ 7.62 (m, 3H), 7.95 (m, 4H), 8.22 (s, 1H), 12.47 (s, 1H) 1 H NMR:? 7.62 (m, 3H), 7.95 (m, 4H), 8.22

<단계 3> 7-(2-nitrophenyl)-1-phenyl-1H-indazole의 합성<Step 3> Synthesis of 7- (2-nitrophenyl) -1-phenyl-1H-indazole

Figure 112012102405784-pat00060
Figure 112012102405784-pat00060

준비예 1의 <단계 3>에서 사용된 5-(2-nitrophenyl)-1H-indazole 대신 상기 준비예 4의 <단계 2>에서 얻은 7-(2-nitrophenyl)-1H-indazole (11.04 g, 46.17 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 3>과 동일한 과정을 수행하여 7-(2-nitrophenyl)-1-phenyl-1H-indazole을 얻었다.(2-nitrophenyl) -1H-indazole (11.04 g, 46.17 g) obtained in Step 2 of Preparation Example 4 was used instead of 5- (2-nitrophenyl) -1H-indazole used in Step 3 of Preparation Example 1 (2-nitrophenyl) -1-phenyl-1H-indazole was obtained by following the procedure of <Step 3> of Preparation Example 1,

1H NMR: δ 7.58 (m, 8H), 7.89 (m, 2H), 8.02 (m, 2H), 8.39 (s, 1H) 1 H NMR: δ 7.58 (m , 8H), 7.89 (m, 2H), 8.02 (m, 2H), 8.39 (s, 1H)

<단계 4> 화합물 IC-6의 합성<Step 4> Synthesis of Compound IC-6

Figure 112012102405784-pat00061
Figure 112012102405784-pat00061

준비예 1의 <단계 4>에서 사용된 5-(2-nitrophenyl)-1-phenyl-1H-indazole 대신 상기 준비예 4의 <단계 3>에서 얻은 7-(2-nitrophenyl)-1-phenyl-1H-indazole (5.01 g, 15.91 mmol)을 사용하는 것을 제외하고는 준비예 1의 <단계 4>와 동일한 과정을 수행하여 화합물 IC-6을 얻었다.(2-nitrophenyl) -1-phenyl-1H-indazole obtained in Step 3 of Preparation Example 4 was used instead of 5- (2-nitrophenyl) 1H-indazole (5.01 g, 15.91 mmol) was used in the same manner as in <Step 4> of Preparation Example 1 to obtain a compound IC-6.

1H NMR: δ 7.28 (t, 1H), 7.55 (m, 7H), 7.92 (d, 2H), 8.14 (d, 1H), 8.33 (s, 1H), 10.70 (s, 1H)
1 H NMR: 8 7.28 (s, IH), 7.55 (m, 7H), 7.92 (d, 2H), 8.14

[[ 준비예Preparation Example 5] 화합물  5] Compound ICIC -7의 합성Synthesis of -7

<단계 1> 5-(2-nitrophenyl)-1-o-tolyl-1H-indazole의 합성<Step 1> Synthesis of 5- (2-nitrophenyl) -1-o-tolyl-1H-indazole

Figure 112012102405784-pat00062
Figure 112012102405784-pat00062

준비예 1의 <단계 3>에서 사용된 Iodobenzene 대신 1-bromo-2-methylbenzene (11.85 g, 69.26 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 3>과 동일한 과정을 수행하여 5-(2-nitrophenyl)-1-o-tolyl-1H-indazole을 얻었다.Except that 1-bromo-2-methylbenzene (11.85 g, 69.26 mmol) was used in place of the iodobenzene used in Step 3 of Preparation Example 1, the procedure of Step 3 of Preparation Example 1 was repeated to obtain 5 - (2-nitrophenyl) -1-o-tolyl-1H-indazole.

1H-NMR: δ 1.92 (s, 3H), 7.33 (m, 3H), 7.49 (d, 1H), 7.65 (m, 2H), 7.90 (t, 1H), 8.04 (m, 2H), 8.07 (s, 1H), 8.39 (m, 2H) 1 H-NMR: δ 1.92 ( s, 3H), 7.33 (m, 3H), 7.49 (d, 1H), 7.65 (m, 2H), 7.90 (t, 1H), 8.04 (m, 2H), 8.07 ( s, 1 H), 8.39 (m, 2 H)

<단계 2> 화합물 IC-7 의 합성<Step 2> Synthesis of Compound IC-7

Figure 112012102405784-pat00063
Figure 112012102405784-pat00063

준비예 1의 <단계 4>에서 사용된 5-(2-nitrophenyl)-1-phenyl-1H-indazole 대신 상기 준비예 5의 <단계 1>에서 얻은 5-(2-nitrophenyl)-1-o-tolyl-1H-indazole (5.24 g, 15.91 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 4>와 동일한 과정을 수행하여 화합물 IC-7를 얻었다.(2-nitrophenyl) -1-o-butanol obtained in Step 1 of Preparation Example 5 was used instead of 5- (2-nitrophenyl) -1- The compound IC-7 was obtained by following the procedure of <Step 4> of Preparation Example 1, except that tolyl-1H-indazole (5.24 g, 15.91 mmol) was used.

1H-NMR: δ 1.93 (s, 3H), 7.35 (m, 5H), 7.49 (m, 2H), 7.63 (d, 1H), 8.11 (d, 1H), 8.35 (m, 2H), 10.11 (s, 1H)
1 H-NMR: δ 1.93 ( s, 3H), 7.35 (m, 5H), 7.49 (m, 2H), 7.63 (d, 1H), 8.11 (d, 1H), 8.35 (m, 2H), 10.11 ( s, 1 H)

[준비예 6] 화합물 IC-8의 합성[Preparation Example 6] Synthesis of Compound IC-8

<단계 1> 5-(5-bromo-2-nitrophenyl)-1H-indazole의 합성<Step 1> Synthesis of 5- (5-bromo-2-nitrophenyl) -1H-indazole

Figure 112012102405784-pat00064
Figure 112012102405784-pat00064

준비예 1의 <단계 2>에서 사용된 1-bromo-2-nitrobenzene 대신 2,4-dibromo-1-nitrobenzene (21.18 g, 75.41 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 2>와 동일한 과정을 수행하여 5-(5-bromo-2-nitrophenyl)-1H-indazole을 얻었다.Except that 2,4-dibromo-1-nitrobenzene (21.18 g, 75.41 mmol) was used instead of 1-bromo-2-nitrobenzene used in <Step 2> in Preparation Example 1, (5-bromo-2-nitrophenyl) -1H-indazole was obtained.

1H NMR: δ 7.63 (d, 1H), 7.73 (s, 1H), 7.99 (d, 1H), 8.06 (s, 1H), 8.21 (m, 2H), 8.37 (d, 1H), 12.13 (s, 1H) 1 H NMR: δ 7.63 (d , 1H), 7.73 (s, 1H), 7.99 (d, 1H), 8.06 (s, 1H), 8.21 (m, 2H), 8.37 (d, 1H), 12.13 (s , 1H)

<단계 2> 5-(5-bromo-2-nitrophenyl)-1-phenyl-1H-indazole의 합성<Step 2> Synthesis of 5- (5-bromo-2-nitrophenyl) -1-phenyl-1H-indazole

Figure 112012102405784-pat00065
Figure 112012102405784-pat00065

준비예 1의 <단계 3>에서 사용된 5-(2-nitrophenyl)-1H-indazole 대신 상기 준비예 6의 <단계 1>에서 얻은 5-(5-bromo-2-nitrophenyl)-1H-indazole (14.69 g, 46.17 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 3>과 동일한 과정을 수행하여 5-(5-bromo-2-nitrophenyl)-1-phenyl-1H-indazole을 얻었다.5-bromo-2-nitrophenyl) -1H-indazole (prepared in Step 1 of Preparation Example 6) was used instead of 5- (2-nitrophenyl) (5-bromo-2-nitrophenyl) -1-phenyl-1H-indazole was obtained in the same manner as in <Step 3> of Preparation Example 1, except that 14.69 g (46.17 mmol)

1H NMR: δ 7.44 (t, 1H), 7.60 (m, 5H), 7.72 (s, 1H), 7.97 (d, 1H), 8.07 (s, 1H), 8.19 (d, 1H), 8.38 (m, 2H) 1 H NMR: δ 7.44 (t , 1H), 7.60 (m, 5H), 7.72 (s, 1H), 7.97 (d, 1H), 8.07 (s, 1H), 8.19 (d, 1H), 8.38 (m , 2H)

<단계 3> 7-bromo-3-phenyl-3,10-dihydropyrrolo[3,2-a]carbazole 의 합성<Step 3> Synthesis of 7-bromo-3-phenyl-3,10-dihydropyrrolo [3,2-a]

Figure 112012102405784-pat00066
Figure 112012102405784-pat00066

준비예 1의 <단계 4>에서 사용된 5-(2-nitrophenyl)-1-phenyl-1H-indazole 대신 상기 준비예 6의 <단계 2>에서 얻은 5-(5-bromo-2-nitrophenyl)-1-phenyl-1H-indazole (6.27 g, 15.91 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 4>와 동일한 과정을 수행하여 7-bromo-3-phenyl-3,10-dihydropyrrolo[3,2-a]carbazole을 얻었다.(5-bromo-2-nitrophenyl) -1-phenyl-1H-indazole obtained in Step 2 of Preparation Example 6 was used instead of 5- (2-nitrophenyl) Bromo-3-phenyl-3,10-dihydropyrrolo [2,3-d] pyrimidin-2-one was obtained by following the procedure of <Step 4> of Preparation Example 1, 3,2-a] carbazole.

1H-NMR: δ 7.52 (m, 8H), 8.03 (s, 1H), 8.33 (m, 2H), 10.55 (s, 1H) 1 H-NMR:? 7.52 (m, 8H), 8.03 (s, IH), 8.33 (m, 2H), 10.55

<단계 4> 화합물 IC-8의 합성<Step 4> Synthesis of Compound IC-8

Figure 112012102405784-pat00067
Figure 112012102405784-pat00067

준비예 1의 <단계 3>에서 사용된 5-(2-nitrophenyl)-1H-indazole 대신 상기 준비예 6의 <단계 3>에서 얻은 7-bromo-3-phenyl-3,10-dihydropyrrolo[3,2-a]carbazole (3.98 g, 11 mmol) 을 사용한 것을 제외하고, 준비예1의 <단계 3>과 동일한 방법으로 화합물 IC-8을 얻었다. Bromo-3-phenyl-3,10-dihydropyrrolo [3, 4-d] pyrimidine obtained in Step 3 of Preparation Example 6 was used instead of 5- (2-nitrophenyl) 2-a] carbazole (3.98 g, 11 mmol) was used in place of the compound obtained in Step 3 of Preparation Example 1, compound IC-8 was obtained.

1H NMR: δ 7.25 (d, 1H), 7.54 (m, 11H), 7.72 (s, 1H), 7.88 (d, 1H), 8.34 (m, 2H)
1 H NMR: δ 7.25 (d , 1H), 7.54 (m, 11H), 7.72 (s, 1H), 7.88 (d, 1H), 8.34 (m, 2H)

[준비예 7] 화합물 IC-9의 합성[Preparation Example 7] Synthesis of compound IC-9

<단계 1> 6-(5-bromo-2-nitrophenyl)-1H-indazole의 합성<Step 1> Synthesis of 6- (5-bromo-2-nitrophenyl) -1H-indazole

Figure 112012102405784-pat00068
Figure 112012102405784-pat00068

준비예 1의 <단계 2>에서 사용된 1-bromo-2-nitrobenzene 대신 2,4-dibromo-1-nitrobenzene (21.18 g, 75.41 mmol)을 사용하고, 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 대신 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (22.09 g, 90.49 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 2>와 동일한 과정을 수행하여 6-(5-bromo-2-nitrophenyl)-1H-indazole을 얻었다.2,4-dibromo-1-nitrobenzene (21.18 g, 75.41 mmol) was used instead of 1-bromo-2-nitrobenzene used in Step 2 of Preparation Example 1 and 5- (4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-indazole (22.09 g, (5-bromo-2-nitrophenyl) -1H-indazole was obtained by following the procedure of <Step 2> of Preparation Example 1,

1H NMR: δ 7.49 (d, 1H), 7.71 (s, 1H), 7.80 (s, 1H), 7.98 (d, 2H), 8.21 (m, 2H), 12.25 (s, 1H) 1 H NMR: 8 7.49 (s, IH), 7.71 (s, IH), 7.80

<단계 2> 6-(5-bromo-2-nitrophenyl)-1-phenyl-1H-indazole의 합성<Step 2> Synthesis of 6- (5-bromo-2-nitrophenyl) -1-phenyl-1H-indazole

Figure 112012102405784-pat00069
Figure 112012102405784-pat00069

준비예 1의 <단계 3>에서 사용된 5-(2-nitrophenyl)-1H-indazole 대신 상기 준비예 7의 <단계 1>에서 얻은 6-(5-bromo-2-nitrophenyl)-1H-indazole (14.69 g, 46.17 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 3>과 동일한 과정을 수행하여 6-(5-bromo-2-nitrophenyl)-1-phenyl-1H-indazole을 얻었다.(5-bromo-2-nitrophenyl) -1H-indazole (prepared in Step 1 of Preparation Example 7) was used instead of 5- (2-nitrophenyl) 6-bromo-2-nitrophenyl) -1-phenyl-1H-indazole was obtained in the same manner as in <Step 3> of Preparation Example 1, except that 14.69 g (46.17 mmol)

1H NMR: δ 7.47 (m, 2H), 7.61 (m, 4H), 7.70 (s, 1H), 7.81 (s, 1H), 7.99 (d, 2H), 8.21 (d, 1H), 8.40 (s, 1H) 1 H NMR: 8 7.47 (m, 2H), 7.61 (m, 4H), 7.70 (s, , 1H)

<단계 3> 7-bromo-1-phenyl-1,10-dihydropyrazolo[3,4-a]carbazole의 합성<Step 3> Synthesis of 7-bromo-1-phenyl-1,10-dihydropyrazolo [3,4-a]

Figure 112012102405784-pat00070
Figure 112012102405784-pat00070

준비예 1의 <단계 4>에서 사용된 5-(2-nitrophenyl)-1-phenyl-1H-indazole 대신 상기 준비예 7의 <단계 2>에서 얻은 6-(5-bromo-2-nitrophenyl)-1-phenyl-1H-indazole (6.27 g, 15.91 mmol)을 사용하는 것을 제외하고는, 준비예 1의 <단계 4>와 동일한 과정을 수행하여 7-bromo-1-phenyl-1,10-dihydropyrazolo[3,4-a]carbazole을 얻었다.(5-bromo-2-nitrophenyl) -1-phenyl-1H-indazole obtained in Step 2 of Preparation Example 7 was used instead of 5- (2-nitrophenyl) 1-phenyl-1H-indazole (6.27 g, 15.91 mmol) was used in place of 7-bromo-1-phenyl- 3,4-a] carbazole.

1H-NMR: δ 7.27 (d, 1H), 7.52 (m, 7H), 7.93 (d, 1H), 8.05 (s, 1H), 8.33 (s, 1H), 10.22 (s, 1H) 1 H-NMR:? 7.27 (s, 1H), 7.52 (m, 7H), 7.93 (d,

<단계 4> 화합물 IC-9의 합성<Step 4> Synthesis of compound IC-9

Figure 112012102405784-pat00071
Figure 112012102405784-pat00071

준비예 1의 <단계 3>에서 사용된 5-(2-nitrophenyl)-1H-indazole 대신 상기 준비예 7의 <단계 3>에서 얻은 7-bromo-1-phenyl-1,10-dihydropyrazolo[3,4-a]carbazole (3.98 g, 11 mmol)을 사용한 것을 제외하고, 준비예1의 <단계 3>과 동일한 방법으로 화합물 IC-9을 얻었다. Bromo-1-phenyl-1,10-dihydropyrazolo [3,3-b] pyridine obtained in Step 3 of Preparation Example 7 was used instead of 5- (2-nitrophenyl) 4-a] carbazole (3.98 g, 11 mmol) was used in place of the compound obtained in Step 3 of Preparation Example 1.

1H NMR: δ 7.26 (m, 2H), 7.58 (m, 10H), 7.74 (s, 1H), 7.86 (d, 1H), 7.95 (d, 1H), 8.43 (s, 1H)
1 H NMR:? 7.26 (m, 2H), 7.58 (m, IH), 7.74 (s, IH), 7.86

[[ 합성예Synthetic example 1] 화합물 C-1의 합성 1] Synthesis of Compound C-1

Figure 112012102405784-pat00072
Figure 112012102405784-pat00072

질소 기류 하에서 준비예 1에서 합성된 화합물 IC-1 (3.76 g, 13.29 mmol), 2-(4-bromophenyl)triphenylene (10.18 g, 26.57 mmol), Cu powder(0.17 g, 2.66 mmol), K2CO3(3.66 g, 26.57 mmol), Na2SO4(3.78 g, 26.57 mmol) 및 nitrobenzene(100 ml)를 혼합한 다음, 190℃에서 12시간 동안 교반하였다. (3.76 g, 13.29 mmol), 2- (4-bromophenyl) triphenylene (10.18 g, 26.57 mmol), Cu powder (0.17 g, 2.66 mmol) synthesized in Preparation Example 1, K 2 CO 3 (3.66 g, 26.57 mmol), Na 2 SO 4 (3.78 g, 26.57 mmol) and nitrobenzene (100 ml) were mixed and then stirred at 190 ° C for 12 hours.

반응이 종결된 후 nitrobenzene을 제거하고 메틸렌클로라이드로 유기층을 분리한 다음, MgSO4를 사용하여 물을 제거하였다. 유기층의 용매를 제거한 후 컬럼크로마토그래피로 정제하여 화합물 C-1 (5.37 g, 수율: 69%)을 얻었다. After the reaction was completed, the nitrobenzene was removed, the organic layer was separated with methylene chloride, and then water was removed using MgSO 4 . The solvent of the organic layer was removed, and the residue was purified by column chromatography to obtain Compound C-1 (5.37 g, yield 69%).

GC-Mass (이론치: 585.69 g/mol, 측정치: 585 g/mol)
GC-Mass (calculated: 585.69 g / mol, measured: 585 g / mol)

[[ 합성예Synthetic example 2] 화합물 C-2의 합성 2] Synthesis of Compound C-2

Figure 112012102405784-pat00073
Figure 112012102405784-pat00073

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 4-(4-bromophenyl)-6-phenyldibenzo[b,d]thiophene (11.03 g, 26.57 mmol)을 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-2 (4.92 g, 수율: 60%)을 얻었다.Except that 4- (4-bromophenyl) -6-phenyldibenzo [b, d] thiophene (11.03 g, 26.57 mmol) was used instead of 2- (4-bromophenyl) triphenylene used in Synthesis Example 1, The compound C-2 (4.92 g, yield: 60%) was obtained.

GC-Mass (이론치: 617.76 g/mol, 측정치: 617 g/mol)
GC-Mass (calculated: 617.76 g / mol, measured: 617 g / mol)

[[ 합성예Synthetic example 3] 화합물 C-3의 합성 3] Synthesis of Compound C-3

Figure 112012102405784-pat00074
Figure 112012102405784-pat00074

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 2-bromo-6-phenylpyridine(6.22 g, 26.57 mmol)을 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-3 (4.12 g, 수율: 71%)을 얻었다.The procedure of Synthesis Example 1 was repeated except that 2-bromo-6-phenylpyridine (6.22 g, 26.57 mmol) was used instead of 2- (4-bromophenyl) triphenylene used in Synthesis Example 1, (4.12 g, yield: 71%).

GC-Mass (이론치: 436.51 g/mol, 측정치: 436 g/mol)
GC-Mass (calculated: 436.51 g / mol, measured: 436 g / mol)

[[ 합성예Synthetic example 4] 화합물 C-4의 합성 4] Synthesis of Compound C-4

Figure 112012102405784-pat00075
Figure 112012102405784-pat00075

질소 기류 하에서 준비예 1에서 합성된 화합물 IC-1 (1.66 g, 5.85 mmol), 2-chloro-4,6-diphenylpyrimidine (2.09 g, 7.85 mmol), NaH (2.11 g, 8.78 mmol) 및 DMF(80 ml)를 혼합한 다음, 상온에서 3시간 동안 교반하였다. 반응이 종결된 후, 물을 넣고 고체 생성물을 필터링한 후, 컬럼 크로마토그래피로 정제하여 화합물 C-4 (2.25 g, 수율: 75%)를 얻었다.(1.66 g, 5.85 mmol), 2-chloro-4,6-diphenylpyrimidine (2.09 g, 7.85 mmol), NaH (2.11 g, 8.78 mmol) synthesized in Preparation Example 1 and DMF ml) were mixed, followed by stirring at room temperature for 3 hours. After the reaction was completed, water was added thereto, and the solid product was filtered, and then purified by column chromatography to obtain Compound C-4 (2.25 g, yield: 75%).

GC-Mass (이론치: 513.59 g/mol, 측정치: 513 g/mol)
GC-Mass (theory: 513.59 g / mol, measured: 513 g / mol)

[[ 합성예Synthetic example 5] 화합물 C-5의 합성 5] Synthesis of Compound C-5

Figure 112012102405784-pat00076
Figure 112012102405784-pat00076

합성예 4에서 사용된 2-chloro-4,6-diphenylpyrimidine 대신 2-chloro-4,6-diphenyl-1,3,5-triazine (2.10 g, 7.85 mmol)을 사용하는 것을 제외하고는, 합성예 4와 동일한 과정을 수행하여 화합물 C-5 (2.07 g, 수율: 69%)을 얻었다.Except that 2-chloro-4,6-diphenyl-1,3,5-triazine (2.10 g, 7.85 mmol) was used instead of 2-chloro-4,6-diphenylpyrimidine used in Synthesis Example 4 4, the compound C-5 (2.07 g, yield: 69%) was obtained.

GC-Mass (이론치: 514.58 g/mol, 측정치: 514 g/mol)
GC-Mass (theory: 514.58 g / mol, measured: 514 g / mol)

[[ 합성예Synthetic example 6] 화합물 C-6의 합성 6] Synthesis of Compound C-6

Figure 112012102405784-pat00077
Figure 112012102405784-pat00077

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 4-bromo-N,N-diphenylaniline (8.61 g, 26.57 mmol)를 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-6 (4.34 g, 수율: 62%)을 얻었다.The procedure of Synthesis Example 1 was repeated except that 4-bromo-N, N-diphenylaniline (8.61 g, 26.57 mmol) was used instead of 2- (4-bromophenyl) triphenylene used in Synthesis Example 1, -6 (4.34 g, yield: 62%).

GC-Mass (이론치: 526.63 g/mol, 측정치: 526 g/mol)
GC-Mass (calculated: 526.63 g / mol, measured: 526 g / mol)

[[ 합성예Synthetic example 7] 화합물 C-7의 합성 7] Synthesis of Compound C-7

Figure 112012102405784-pat00078
Figure 112012102405784-pat00078

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 3-bromo-9-(4,6-diphenyl-1,3,5-triazin-2-yl)-9H-carbazole (12.68 g, 26.57 mmol)를 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-7 (5.24 g, 수율: 58%)을 얻었다.3-bromo-9- (4,6-diphenyl-1,3,5-triazin-2-yl) -9H-carbazole (12.68 g, 26.57 mmol) was used in place of 2- (4-bromophenyl) triphenylene used in Synthesis Example 1 ), The same procedure as in Synthesis Example 1 was conducted to obtain Compound C-7 (5.24 g, yield: 58%).

GC-Mass (이론치: 679.77 g/mol, 측정치: 679 g/mol)
GC-Mass (calculated: 679.77 g / mol, measured: 679 g / mol)

[합성예 8] 화합물 C-8의 합성[Synthesis Example 8] Synthesis of Compound C-8

Figure 112012102405784-pat00079
Figure 112012102405784-pat00079

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 10-(4-bromophenyl)-9,9-dimethyl-9,10-dihydroacridine (9.67 g, 26.57 mmol)를 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-8 (5.72 g, 수율: 76%)을 얻었다.Except that 10- (4-bromophenyl) -9,9-dimethyl-9,10-dihydroacridine (9.67 g, 26.57 mmol) was used instead of 2- (4-bromophenyl) triphenylene used in Synthesis Example 1, Compound C-8 (5.72 g, yield: 76%) was obtained by carrying out the same procedure as in Example 1.

GC-Mass (이론치: 566.69 g/mol, 측정치: 566 g/mol)
GC-Mass (calculated: 566.69 g / mol, measured: 566 g / mol)

[[ 합성예Synthetic example 9] 화합물 C-9의 합성 9] Synthesis of Compound C-9

Figure 112012102405784-pat00080
Figure 112012102405784-pat00080

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 (4-bromophenyl)triphenylsilane(11.04 g, 26.57 mmol)를 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-9 (4.68 g, 수율: 57%)를 얻었다.The same procedure as in Synthesis Example 1 was repeated, except that (4-bromophenyl) triphenylsilane (11.04 g, 26.57 mmol) was used instead of 2- (4-bromophenyl) triphenylene used in Synthesis Example 1, 4.68 g, yield: 57%).

GC-Mass (이론치: 617.81 g/mol, 측정치: 617 g/mol)
GC-Mass (theory: 617.81 g / mol, measured: 617 g / mol)

[[ 합성예Synthetic example 10] 화합물 C-10의 합성 10] Synthesis of Compound C-10

Figure 112012102405784-pat00081
Figure 112012102405784-pat00081

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 2-(3-bromophenyl)-4,6-diphenyl-1,3,5-triazine(10.32 g, 26.57 mmol)를 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-10 (6.28 g, 수율: 80%)을 얻었다.Except that 2- (3-bromophenyl) -4,6-diphenyl-1,3,5-triazine (10.32 g, 26.57 mmol) was used instead of 2- (4-bromophenyl) triphenylene used in Synthesis Example 1 , Compound C-10 (6.28 g, yield: 80%) was obtained by carrying out the same processes as in Synthesis Example 1.

GC-Mass (이론치: 590.67 g/mol, 측정치: 590 g/mol)
GC-Mass (calculated: 590.67 g / mol, measured: 590 g / mol)

[합성예 11] 화합물 C-11의 합성[Synthesis Example 11] Synthesis of Compound C-11

Figure 112012102405784-pat00082
Figure 112012102405784-pat00082

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 2-(4'-bromo-[1,1'-biphenyl]-3-yl)-4,6-diphenyl-1,3,5-triazine (12.34 g, 26.57 mmol)을 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-11 (7.44 g, 수율: 84%)을 얻었다.(4'-bromo- [1,1'-biphenyl] -3-yl) -4,6-diphenyl-1,3,5-triazine instead of 2- (4-bromophenyl) triphenylene used in Synthesis Example 1 (7.44 g, yield: 84%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that the compound C-11 (12.34 g, 26.57 mmol) was used.

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[[ 합성예Synthetic example 12] 화합물 C-12의 합성 12] Synthesis of Compound C-12

Figure 112012102405784-pat00083
Figure 112012102405784-pat00083

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 2-(3'-bromo-[1,1'-biphenyl]-3-yl)-4,6-diphenyl-1,3,5-triazine (12.34 g, 26.57 mmol)을 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-12 (7.26 g, 수율: 82%)를 얻었다.(3'-bromo- [1,1'-biphenyl] -3-yl) -4,6-diphenyl-1,3,5-triazine instead of 2- (4-bromophenyl) triphenylene used in Synthesis Example 1 (7.26 g, yield: 82%) was obtained by following the same procedure as in Synthesis Example 1, except that the compound C-12 (12.34 g, 26.57 mmol) was used.

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[[ 합성예Synthetic example 13] 화합물 C-13의 합성 13] Synthesis of Compound C-13

Figure 112012102405784-pat00084
Figure 112012102405784-pat00084

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 2-(7-bromo-9,9-dimethyl-9H-fluoren-2-yl)-4,6-diphenyl-1,3,5-triazine (13.40g, 26.57 mmol)을 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-13 (5.73 g, 수율: 61%)을 얻었다.(7-bromo-9,9-dimethyl-9H-fluoren-2-yl) -4,6-diphenyl-1,3,5-triazine was used in place of 2- (4-bromophenyl) triphenylene used in Synthesis Example 1 (5.73 g, yield: 61%) was obtained by carrying out the same procedure as in Synthesis Example 1, except that the compound C-13 (13.40 g, 26.57 mmol) was used.

GC-Mass (이론치: 706.83 g/mol, 측정치: 706 g/mol)
GC-Mass (calculated: 706.83 g / mol, measured: 706 g / mol)

[[ 합성예Synthetic example 14] 화합물 C-14의 합성 14] Synthesis of Compound C-14

Figure 112012102405784-pat00085
Figure 112012102405784-pat00085

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 N-([1,1'-biphenyl]-4-yl)-N-(4-bromophenyl)-[1,1'-biphenyl]-4-amine (12.66g, 26.57 mmol)을 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-14 (6.31 g, 수율: 70%)를 얻었다.Instead of 2- (4-bromophenyl) triphenylene used in Synthesis Example 1, N - ([1,1'-biphenyl] -4-yl) -N- (4-bromophenyl) - [ -amine (12.66 g, 26.57 mmol), the same procedure as in Synthesis Example 1 was conducted to obtain Compound C-14 (6.31 g, yield: 70%).

GC-Mass (이론치: 678.82 g/mol, 측정치: 678 g/mol)
GC-Mass (theory: 678.82 g / mol, measured: 678 g / mol)

[합성예 15] 화합물 C-15의 합성[Synthesis Example 15] Synthesis of Compound C-15

Figure 112012102405784-pat00086
Figure 112012102405784-pat00086

2-(4-bromophenyl)triphenylene 대신 N-([1,1'-biphenyl]-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine (13.72g, 26.57 mmol)을 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-15 (6.21 g, 수율: 65%)를 얻었다.Substituting N - ([1,1'-biphenyl] -4-yl) -N- (4-bromophenyl) -9,9-dimethyl-9H-fluoren- 2 -amine (13.72 g , 26.57 mmol), the same procedure as in Synthesis Example 1 was conducted to obtain Compound C-15 (6.21 g, yield: 65%).

GC-Mass (이론치: 718.88 g/mol, 측정치: 718 g/mol)
GC-Mass (calculated: 718.88 g / mol, measured: 718 g / mol)

[합성예 16] 화합물 C-16의 합성[Synthesis Example 16] Synthesis of Compound C-16

Figure 112012102405784-pat00087
Figure 112012102405784-pat00087

합성예 1에서 사용된 2-(4-bromophenyl)triphenylene 대신 10-([1,1'-biphenyl]-4-yl)-2-bromo-9,9-dimethyl-7-phenyl-9,10-dihydroacridine (13.72g, 26.57 mmol)를 사용하는 것을 제외하고는, 합성예 1과 동일한 과정을 수행하여 화합물 C-16 (5.25 g, 수율: 55%)을 얻었다.([1,1'-biphenyl] -4-yl) -2-bromo-9,9-dimethyl-7-phenyl-9,10- Compound C-16 (5.25 g, yield: 55%) was obtained in the same manner as in Synthesis Example 1, except that dihydroacridine (13.72 g, 26.57 mmol) was used.

GC-Mass (이론치: 718.88 g/mol, 측정치: 718 g/mol)
GC-Mass (calculated: 718.88 g / mol, measured: 718 g / mol)

[[ 합성예Synthetic example 17] 화합물 C-17의 합성 17] Synthesis of Compound C-17

Figure 112012102405784-pat00088
Figure 112012102405784-pat00088

합성예 10에서 사용된 화합물 IC-1 대신 준비예 1에서 합성된 화합물 IC-2 (3.76 g, 13.29 mmol)를 사용하는 것을 제외하고는, 합성예 10과 동일한 과정을 수행하여 화합물 C-17 (5.65 g, 수율: 72%)을 얻었다.The procedure of Synthesis Example 10 was repeated except that the compound IC-2 (3.76 g, 13.29 mmol) synthesized in Preparation Example 1 was used instead of the compound IC-1 used in Synthesis Example 10 to obtain the compound C-17 5.65 g, yield: 72%).

GC-Mass (이론치: 590.67 g/mol, 측정치: 590 g/mol)
GC-Mass (calculated: 590.67 g / mol, measured: 590 g / mol)

[[ 합성예Synthetic example 18] 화합물 C-18의 합성 18] Synthesis of Compound C-18

Figure 112012102405784-pat00089
Figure 112012102405784-pat00089

합성예 11에서 사용된 화합물 IC-1 대신 준비예 1에서 합성된 IC-2 (3.76 g, 13.29 mmol)를 사용하는 것을 제외하고는, 합성예 11과 동일한 과정을 수행하여 화합물 C-18 (6.73 g, 수율: 76%)을 얻었다.Compound C-18 (6.73 g, 13.29 mmol) was obtained by following the same procedure as in Synthesis Example 11, except that IC-2 (3.76 g, 13.29 mmol) synthesized in Preparation Example 1 was used instead of Compound IC- g, yield: 76%).

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[합성예 19] 화합물 C-19의 합성[Synthesis Example 19] Synthesis of Compound C-19

Figure 112012102405784-pat00090
Figure 112012102405784-pat00090

합성예 12에서 사용된 화합물 IC-1 대신 준비예 1에서 합성된 화합물 IC-2 (3.76 g, 13.29 mmol)를 사용하는 것을 제외하고는, 합성예 12와 동일한 과정을 수행하여 화합물 C-19 (7.26 g, 수율: 82%)을 얻었다.The same procedure as in Synthesis Example 12 was conducted, except that the compound IC-2 (3.76 g, 13.29 mmol) synthesized in Preparation Example 1 was used instead of the compound IC-1 used in Synthesis Example 12 to obtain the compound C-19 7.26 g, yield: 82%).

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[[ 합성예Synthetic example 20] 화합물 C-20의 합성 20] Synthesis of Compound C-20

Figure 112012102405784-pat00091
Figure 112012102405784-pat00091

합성예 10에서 사용된 화합물 IC-1 대신 준비예 2에서 합성된 화합물 IC-3 (3.76 g, 13.29 mmol)를 사용하는 것을 제외하고는, 합성예 10과 동일한 과정을 수행하여 화합물 C-20 (6.75 g, 수율: 86%)을 얻었다.The procedure of Synthesis Example 10 was repeated except that the compound IC-3 (3.76 g, 13.29 mmol) synthesized in Preparation Example 2 was used instead of the compound IC-1 used in Synthesis Example 10 to obtain the compound C-20 6.75 g, yield: 86%).

GC-Mass (이론치: 590.67 g/mol, 측정치: 590 g/mol)
GC-Mass (calculated: 590.67 g / mol, measured: 590 g / mol)

[[ 합성예Synthetic example 21] 화합물 C-21의 합성 21] Synthesis of Compound C-21

Figure 112012102405784-pat00092
Figure 112012102405784-pat00092

합성예 11에서 사용된 화합물 IC-1 대신 준비예 2에서 합성된 화합물 IC-3 (3.76 g, 13.29 mmol)를 사용하는 것을 제외하고는, 합성예 11과 동일한 과정을 수행하여 화합물 C-21 (6.38 g, 수율: 72%)을 얻었다.The same procedure as in Synthesis Example 11 was conducted, except that the compound IC-3 (3.76 g, 13.29 mmol) synthesized in Preparation Example 2 was used instead of the compound IC-1 used in Synthesis Example 11 to obtain the compound C-21 6.38 g, yield: 72%).

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[[ 합성예Synthetic example 22] 화합물 C-22의 합성 22] Synthesis of Compound C-22

Figure 112012102405784-pat00093
Figure 112012102405784-pat00093

합성예 12에서 사용된 화합물 IC-1 대신 준비예 2에서 합성된 화합물 IC-3 (3.76 g, 13.29 mmol)를 사용하는 것을 제외하고는, 합성예 12와 동일한 과정을 수행하여 화합물 C-22 (6.91 g, 수율: 78%)을 얻었다.The same procedure as in Synthesis Example 12 was conducted, except that the compound IC-3 (3.76 g, 13.29 mmol) synthesized in Preparation Example 2 was used instead of the compound IC-1 used in Synthesis Example 12 to obtain the compound C-22 6.91 g, yield: 78%).

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[[ 합성예Synthetic example 23] 화합물 C-23의 합성 23] Synthesis of Compound C-23

Figure 112012102405784-pat00094
Figure 112012102405784-pat00094

합성예 10에서 사용된 화합물 IC-1 대신 준비예 2에서 합성된 화합물 IC-4 (3.76 g, 13.29 mmol)를 사용하는 것을 제외하고는, 합성예 10과 동일한 과정을 수행하여 화합물 C-23 (4.63 g, 수율: 59%)을 얻었다.The same procedure as in Synthesis Example 10 was carried out except that the compound IC-4 (3.76 g, 13.29 mmol) synthesized in Preparation Example 2 was used instead of the compound IC-1 used in Synthesis Example 10 to obtain the compound C-23 4.63 g, yield: 59%).

GC-Mass (이론치: 590.67 g/mol, 측정치: 590 g/mol)
GC-Mass (calculated: 590.67 g / mol, measured: 590 g / mol)

[[ 합성예Synthetic example 24] 화합물 C-24의 합성 24] Synthesis of Compound C-24

Figure 112012102405784-pat00095
Figure 112012102405784-pat00095

합성예 11에서 사용된 화합물 IC-1 대신 준비예 2에서 합성된 화합물 IC-4 (3.76 g, 13.29 mmol)를 사용하는 것을 제외하고는, 합성예 11과 동일한 과정을 수행하여 화합물 C-24 (5.58 g, 수율: 63%)을 얻었다.The same procedure as in Synthesis Example 11 was carried out except that the compound IC-4 (3.76 g, 13.29 mmol) synthesized in Preparation Example 2 was used instead of the compound IC-1 used in Synthesis Example 11 to obtain the compound C-24 5.58 g, yield: 63%).

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[[ 합성예Synthetic example 25] 화합물 C-25의 합성 25] Synthesis of Compound C-25

Figure 112012102405784-pat00096
Figure 112012102405784-pat00096

합성예 12에서 사용된 화합물 IC-1 대신 준비예 2에서 합성된 화합물 IC-4 (3.76 g, 13.29 mmol)를 사용하는 것을 제외하고는, 합성예 12와 동일한 과정을 수행하여 화합물 C-25 (6.29 g, 수율: 71%)를 얻었다.The procedure of Synthesis Example 12 was repeated except that the compound IC-4 (3.76 g, 13.29 mmol) synthesized in Preparation Example 2 was used instead of the compound IC-1 used in Synthesis Example 12 to obtain the compound C-25 6.29 g, yield: 71%).

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[[ 합성예Synthetic example 26] 화합물 C-26의 합성 26] Synthesis of Compound C-26

Figure 112012102405784-pat00097
Figure 112012102405784-pat00097

합성예 10에서 사용된 화합물 IC-1 대신 준비예 3에서 합성된 화합물 IC-5 (3.76 g, 13.29 mmol)을 사용하는 것을 제외하고는, 합성예 10과 동일한 과정을 수행하여 화합물 C-26 (6.83 g, 수율: 87%)을 얻었다.The same procedure as in Synthesis Example 10 was conducted, except that the compound IC-5 (3.76 g, 13.29 mmol) synthesized in Preparation Example 3 was used instead of the compound IC-1 used in Synthesis Example 10 to obtain the compound C-26 6.83 g, yield: 87%).

GC-Mass (이론치: 590.67 g/mol, 측정치: 590 g/mol)
GC-Mass (calculated: 590.67 g / mol, measured: 590 g / mol)

[[ 합성예Synthetic example 27] 화합물 C-27의 합성 27] Synthesis of Compound C-27

Figure 112012102405784-pat00098
Figure 112012102405784-pat00098

합성예 11에서 사용된 화합물 IC-1 대신 준비예 3에서 합성된 화합물 IC-5 (3.76 g, 13.29 mmol)를 사용하는 것을 제외하고는, 합성예 11과 동일한 과정을 수행하여 화합물 C-27 (6.55 g, 수율: 74%)를 얻었다.The same procedure as in Synthesis Example 11 was carried out except that the compound IC-5 (3.76 g, 13.29 mmol) synthesized in Preparation Example 3 was used instead of the compound IC-1 used in Synthesis Example 11 to obtain the compound C-27 6.55 g, yield: 74%).

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[[ 합성예Synthetic example 28] 화합물 C-28의 합성 28] Synthesis of Compound C-28

Figure 112012102405784-pat00099
Figure 112012102405784-pat00099

합성예 12에서 사용된 화합물 IC-1 대신 준비예 3에서 합성된 화합물 IC-5 (3.76 g, 13.29 mmol)를 사용하는 것을 제외하고는, 합성예 12와 동일한 과정을 수행하여 화합물 C-28 (6.64 g, 수율: 75%)을 얻었다.The procedure of Synthesis Example 12 was repeated except that the compound IC-5 (3.76 g, 13.29 mmol) synthesized in Preparation Example 3 was used instead of the compound IC-1 used in Synthesis Example 12 to obtain the compound C-28 6.64 g, yield: 75%).

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[[ 합성예Synthetic example 29] 화합물 C-29의 합성 29] Synthesis of Compound C-29

Figure 112012102405784-pat00100
Figure 112012102405784-pat00100

합성예 10에서 사용된 화합물 IC-1 대신 준비예 4에서 합성된 화합물 IC-6 (3.76 g, 13.29 mmol)을 사용하는 것을 제외하고는, 합성예 10와 동일한 과정을 수행하여 화합물 C-29 (4.55 g, 수율: 58%)를 얻었다.The procedure of Synthesis Example 10 was repeated except that the compound IC-6 (3.76 g, 13.29 mmol) synthesized in Preparation Example 4 was used instead of the compound IC-1 used in Synthesis Example 10 to obtain the compound C-29 4.55 g, yield: 58%).

GC-Mass (이론치: 590.67 g/mol, 측정치: 590 g/mol)
GC-Mass (calculated: 590.67 g / mol, measured: 590 g / mol)

[합성예 30] 화합물 C-30의 합성[Synthesis Example 30] Synthesis of Compound C-30

Figure 112012102405784-pat00101
Figure 112012102405784-pat00101

합성예 11에서 사용된 화합물 IC-1 대신 준비예 4에서 합성된 화합물 IC-6 (3.76 g, 13.29 mmol)을 사용하는 것을 제외하고는, 합성예 11과 동일한 과정을 수행하여 화합물 C-30 (4.34 g, 수율: 49%)을 얻었다.The same procedure as in Synthesis Example 11 was conducted, except that the compound IC-6 (3.76 g, 13.29 mmol) synthesized in Preparation Example 4 was used instead of the compound IC-1 used in Synthesis Example 11 to obtain Compound C-30 4.34 g, yield: 49%).

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[합성예 31] 화합물 C-31의 합성[Synthesis Example 31] Synthesis of Compound C-31

Figure 112012102405784-pat00102
Figure 112012102405784-pat00102

합성예 12에서 사용된 화합물 IC-1 대신 준비예 4에서 합성된 화합물 IC-6 (3.76 g, 13.29 mmol)을 사용하는 것을 제외하고는, 합성예 12와 동일한 과정을 수행하여 화합물 C-31 (6.11 g, 수율: 69%)을 얻었다.The same procedure as in Synthesis Example 12 was conducted, except that the compound IC-6 (3.76 g, 13.29 mmol) synthesized in Preparation Example 4 was used instead of the compound IC-1 used in Synthesis Example 12 to obtain the compound C-31 6.11 g, yield: 69%).

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[[ 합성예Synthetic example 32] 화합물 C-32의 합성 32] Synthesis of Compound C-32

Figure 112012102405784-pat00103
Figure 112012102405784-pat00103

합성예 10에서 사용된 화합물 IC-1 대신 준비예 5에서 합성된 화합물 IC-7 (3.95 g, 13.29 mmol)을 사용하는 것을 제외하고는, 합성예 10과 동일한 과정을 수행하여 화합물 C-32 (6.43 g, 수율: 80%)를 얻었다.The procedure of Synthesis Example 10 was repeated except that the compound IC-7 (3.95 g, 13.29 mmol) synthesized in Preparation Example 5 was used instead of the compound IC-1 used in Synthesis Example 10 to obtain the compound C-32 6.43 g, yield: 80%).

GC-Mass (이론치: 604.70 g/mol, 측정치: 604 g/mol)
GC-Mass (theory: 604.70 g / mol, measurement: 604 g / mol)

[합성예 33] 화합물 C-33의 합성[Synthesis Example 33] Synthesis of Compound C-33

Figure 112012102405784-pat00104
Figure 112012102405784-pat00104

합성예 11에서 사용된 화합물 IC-1 대신 준비예 5에서 합성된 화합물 IC-7 (3.95 g, 13.29 mmol)을 사용하는 것을 제외하고는, 합성예 11과 동일한 과정을 수행하여 화합물 C-33 (5.97 g, 수율: 66%)을 얻었다.The same procedure as in Synthesis Example 11 was conducted, except that the compound IC-7 (3.95 g, 13.29 mmol) synthesized in Preparation Example 5 was used instead of the compound IC-1 used in Synthesis Example 11 to obtain the compound C-33 5.97 g, yield: 66%).

GC-Mass (이론치: 680.80 g/mol, 측정치: 680 g/mol)
GC-Mass (theory: 680.80 g / mol, measurement: 680 g / mol)

[합성예 34] 화합물 C-34의 합성[Synthesis Example 34] Synthesis of Compound C-34

Figure 112012102405784-pat00105
Figure 112012102405784-pat00105

합성예 12에서 사용된 화합물 IC-1 대신 준비예 5에서 사용된 화합물 IC-7 (3.95 g, 13.29 mmol)을 사용하는 것을 제외하고는, 합성예 12와 동일한 과정을 수행하여 화합물 C-34 (6.51 g, 수율: 72%)을 얻었다.The same procedure as in Synthesis Example 12 was conducted, except that the compound IC-7 (3.95 g, 13.29 mmol) used in Preparation Example 5 was used instead of the compound IC-1 used in Synthesis Example 12 to obtain Compound C-34 6.51 g, yield: 72%).

GC-Mass (이론치: 680.80 g/mol, 측정치: 680 g/mol)
GC-Mass (theory: 680.80 g / mol, measurement: 680 g / mol)

[합성예 35] 화합물 C-35의 합성[Synthesis Example 35] Synthesis of Compound C-35

Figure 112012102405784-pat00106
Figure 112012102405784-pat00106

질소 기류 하에서 준비예 6에서 합성된 화합물 IC-8 (3.20 g, 7.31 mmol), 2,4-diphenyl-6-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,5-triazine (3.81 g, 8.77 mmol), NaOH (0.87 g, 21.93 mmol), Pd(PPh3)4 (0.25 g, 0.21 mmol) 및 1,4-dioxane, H2O (30 ml, 8 ml)를 혼합한 다음, 100℃에서 12시간 동안 교반하였다. 반응 종결 후, 에틸아세테이트로 추출한 다음, MgSO4를 넣고 필터링하였다. 필터링된 유기층의 용매를 제거한 후 컬럼크로마토그래피를 이용하여 화합물 C-35 (2.38 g, 수율: 49%)를 얻었다. The compound IC-8 (3.20 g, 7.31 mmol), 2,4-diphenyl-6- (3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan -2-yl) phenyl) -1,3,5- triazine (3.81 g, 8.77 mmol), NaOH (0.87 g, 21.93 mmol), Pd (PPh 3) 4 (0.25 g, 0.21 mmol) and 1,4- dioxane and H2O (30 ml, 8 ml) were mixed and stirred at 100 ° C for 12 hours. After completion of the reaction, the reaction mixture was extracted with ethyl acetate and then filtered with MgSO 4 . After removing the solvent of the filtered organic layer, Compound C-35 (2.38 g, yield: 49%) was obtained by column chromatography.

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[합성예 36] 화합물 C-36의 합성[Synthesis Example 36] Synthesis of Compound C-36

Figure 112012102405784-pat00107
Figure 112012102405784-pat00107

합성예 35에서 사용된 2,4-diphenyl-6-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,5-triazine 대신 N-([1,1'-biphenyl]-4-yl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-[1,1'-biphenyl]-4-amine (4.59 g, 8.77 mmol)을 사용하는 것을 제외하고는, 합성예 35와 동일한 과정을 수행하여 화합물 C-36 (2.15 g, 수율: 39%)을 얻었다.2,4-diphenyl-6- (3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) -1,3,5-triazine Instead of N - ([1,1'-biphenyl] -4-yl) -N- (4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan- (2.15 g, yield: 39%) was obtained by following the same procedure as in Synthesis Example 35, except that 1,1'-biphenyl] -4-amine (4.59 g, 8.77 mmol) .

GC-Mass (이론치: 754.92 g/mol, 측정치: 754 g/mol)
GC-Mass (calculated: 754.92 g / mol, measured: 754 g / mol)

[합성예 37] 화합물 C-37의 합성[Synthesis Example 37] Synthesis of Compound C-37

Figure 112012102405784-pat00108
Figure 112012102405784-pat00108

합성예 35에서 사용된 2,4-diphenyl-6-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,5-triazine 대신 N-([1,1'-biphenyl]-4-yl)-9,9-dimethyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-9H-fluoren-2-amine (4.94 g, 8.77 mmol)을 사용하는 것을 제외하고는, 합성예 35와 동일한 과정을 수행하여 화합물 C-37 (2.38 g, 수율: 41%)을 얻었다.2,4-diphenyl-6- (3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) -1,3,5-triazine Instead of N - ([1,1'-biphenyl] -4-yl) -9,9-dimethyl-N- (4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan- (2.38 g, yield: 41%) was obtained by carrying out the same processes as in Synthesis Example 35, except that the compound C-37 was used instead of the compound C-37 (4.94 g, 8.77 mmol) .

GC-Mass (이론치: 794.98 g/mol, 측정치: 794 g/mol)
GC-Mass (calculated: 794.98 g / mol, measured: 794 g / mol)

[합성예 38] 화합물 C-38의 합성[Synthesis Example 38] Synthesis of Compound C-38

Figure 112012102405784-pat00109
Figure 112012102405784-pat00109

합성예 35에서 사용된 2,4-diphenyl-6-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,5-triazine 대신 10-([1,1'-biphenyl]-4-yl)-9,9-dimethyl-2-phenyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9,10-dihydroacridine (4.94 g, 8.77 mmol)을 사용하는 것을 제외하고는, 합성예 35와 동일한 과정을 수행하여 화합물 C-38 (2.67 g, 수율: 46%)을 얻었다.2,4-diphenyl-6- (3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) -1,3,5-triazine Instead of 10 - ([1,1'-biphenyl] -4-yl) -9,9-dimethyl-2-phenyl-7- (4,4,5,5- tetramethyl- 1,3,2-dioxaborolan- (2.67 g, yield: 46%) was obtained in the same manner as in Synthesis Example 35, except that the compound C-38 was used in place of the compound C-38.

GC-Mass (이론치: 794.98 g/mol, 측정치: 794 g/mol)
GC-Mass (calculated: 794.98 g / mol, measured: 794 g / mol)

[합성예 39] 화합물 C-39의 합성[Synthesis Example 39] Synthesis of Compound C-39

Figure 112012102405784-pat00110
Figure 112012102405784-pat00110

합성예 35에서 사용된 화합물 IC-8 대신 준비예 7에서 합성된 화합물 IC-9 (3.20 g, 7.31 mmol)를 사용하는 것을 제외하고는, 합성예 35와 동일한 과정을 수행하여 화합물 C-39 (1.95 g, 수율: 40%)을 얻었다.The same procedure as in Synthesis Example 35 was conducted, except that the compound IC-9 (3.20 g, 7.31 mmol) synthesized in Preparation Example 7 was used instead of the compound IC-8 used in Synthesis Example 35 to obtain the compound C-39 1.95 g, yield: 40%).

GC-Mass (이론치: 666.77 g/mol, 측정치: 666 g/mol)
GC-Mass (calculated: 666.77 g / mol, measured: 666 g / mol)

[합성예 40] 화합물 C-40의 합성[Synthesis Example 40] Synthesis of Compound C-40

Figure 112012102405784-pat00111
Figure 112012102405784-pat00111

합성예 36에서 사용된 화합물 IC-8 대신 준비예 7에서 합성된 화합물 IC-9 (3.20 g, 7.31 mmol)를 사용하는 것을 제외하고는, 합성예 36과 동일한 과정을 수행하여 화합물 C-40 (1.76 g, 수율: 32%)을 얻었다.The same procedure as in Synthesis Example 36 was conducted, except that the compound IC-9 (3.20 g, 7.31 mmol) synthesized in Preparation Example 7 was used instead of the compound IC-8 used in Synthesis Example 36 to obtain the compound C-40 1.76 g, yield: 32%).

GC-Mass (이론치: 754.92 g/mol, 측정치: 754 g/mol)
GC-Mass (calculated: 754.92 g / mol, measured: 754 g / mol)

[합성예 41] 화합물 C-41의 합성[Synthesis Example 41] Synthesis of Compound C-41

Figure 112012102405784-pat00112
Figure 112012102405784-pat00112

합성예 37에서 사용된 화합물 IC-8 대신 준비예 7에서 합성된 화합물 IC-9 (3.20 g, 7.31 mmol)를 사용하는 것을 제외하고는, 합성예 37과 동일한 과정을 수행하여 화합물 C-41 (1.45 g, 수율: 25%)을 얻었다.(C-41) was obtained in the same manner as in Synthesis Example 37, except that the compound IC-9 (3.20 g, 7.31 mmol) synthesized in Preparation Example 7 was used instead of the compound IC- 1.45 g, yield: 25%).

GC-Mass (이론치: 794.98 g/mol, 측정치: 794 g/mol)
GC-Mass (calculated: 794.98 g / mol, measured: 794 g / mol)

[합성예 42] 화합물 C-42의 합성[Synthesis Example 42] Synthesis of Compound C-42

Figure 112012102405784-pat00113
Figure 112012102405784-pat00113

합성예 38에서 사용된 화합물 IC-8 대신 준비예 7에서 합성된 화합물 IC-9 (3.20 g, 7.31 mmol)를 사용하는 것을 제외하고는, 합성예 38과 동일한 과정을 수행하여 화합물 C-42 (2.15 g, 수율: 37%)을 얻었다.The same procedure as in Synthesis Example 38 was conducted, except that the compound IC-9 (3.20 g, 7.31 mmol) synthesized in Preparation Example 7 was used instead of the compound IC-8 used in Synthesis Example 38 to obtain the compound C-42 2.15 g, yield: 37%).

GC-Mass (이론치: 794.98 g/mol, 측정치: 794 g/mol)
GC-Mass (calculated: 794.98 g / mol, measured: 794 g / mol)

[실시예 1] 유기 EL 소자의 제조[Example 1] Production of organic EL device

합성예 1에서 합성한 화합물 C-1을 통상적으로 알려진 방법으로 고순도 승화정제를 한 후 아래의 과정에 따라 녹색 유기 EL 소자를 제작하였다.Compound C-1 synthesized in Synthesis Example 1 was subjected to high-purity sublimation purification by a conventionally known method, and then a green organic EL device was fabricated according to the following procedure.

먼저, ITO (Indium tin oxide)가 1500 Å 두께로 박막 코팅된 유리 기판을 증류수 초음파로 세척하였다. 증류수 세척이 끝나면, 이소프로필 알코올, 아세톤, 메탄올 등의 용제로 초음파 세척을 하고 건조시킨 후, UV OZONE 세정기 (Power sonic 405, 화신테크)로 이송시킨 다음, UV를 이용하여 상기 기판을 5분간 세정하고 진공 증착기로 기판을 이송하였다.First, glass substrate coated with ITO (Indium tin oxide) thin film of 1500 Å thickness was cleaned with distilled water ultrasonic wave. After the distilled water was washed, the substrate was ultrasonically washed with a solvent such as isopropyl alcohol, acetone, or methanol, and dried. Then, the substrate was transferred to a UV OZONE cleaner (Power sonic 405, Hoshin Tech) And the substrate was transferred to a vacuum evaporator.

상기와 같이 준비된 ITO 투명 전극 위에, m-MTDATA (60 nm)/TCTA (80 nm)/화합물 C-1 + 10 % Ir(ppy)3 (300nm)/BCP (10 nm)/Alq3 (30 nm)/LiF (1 nm)/Al (200 nm) 순으로 적층하여 유기 EL 소자를 제작하였다. (60 nm) / TCTA (80 nm) / Compound C-1 + 10% Ir (ppy) 3 (300 nm) / BCP (10 nm) / Alq 3 (30 nm) on the ITO transparent electrode prepared above. ) / LiF (1 nm) / Al (200 nm) were stacked in this order to fabricate an organic EL device.

사용된 m-MTDATA, TCTA, Ir(ppy)3, 및 BCP의 구조는 하기와 같다.The structures of m-MTDATA, TCTA, Ir (ppy) 3 and BCP used are as follows.

Figure 112012102405784-pat00114
Figure 112012102405784-pat00114

Figure 112012102405784-pat00115

Figure 112012102405784-pat00115

[실시예 2 ~ 42] - 유기 EL 소자의 제조[Examples 2 to 42] - Preparation of organic EL device

실시예 1에서 발광층의 형성시 호스트 물질로서 사용된 화합물 C-1 대신 합성예 2 내4251에서 각각 합성된 화합물 C-2 내지 C-42를 사용하는 것을 제외하고는, 실시예 1과 동일하게 수행하여 유기 EL 소자를 제조하였다.
The procedure of Example 1 was repeated, except that the compounds C-2 to C-42 synthesized in 4251 in Synthesis Example 2 were used instead of the compound C-1 used as the host material in the formation of the light emitting layer in Example 1 Thereby preparing an organic EL device.

[비교예 1] 유기 EL 소자의 제조[Comparative Example 1] Production of organic EL device

실시예 1에서 발광층 형성시 발광 호스트 물질로서 사용된 화합물 C-1 대신 CBP를 사용하는 것을 제외하고는, 실시예 1과 동일한 과정으로 유기 EL 소자를 제조하였다. 사용된 CBP의 구조는 하기와 같다.An organic EL device was prepared in the same manner as in Example 1, except that CBP was used instead of the compound C-1 used as a luminescent host material in forming the light emitting layer in Example 1. The structure of CBP used is as follows.

Figure 112012102405784-pat00116

Figure 112012102405784-pat00116

[평가예][Evaluation example]

실시예 1 내지 42, 및 비교예 1에서 각각 제조된 유기 EL 소자에 대하여, 전류밀도 10 mA/㎠에서의 구동전압, 전류효율 및 발광 피크를 측정하였고, 그 결과를 하기 표 1에 나타내었다.The organic EL devices manufactured in Examples 1 to 42 and Comparative Example 1 were measured for driving voltage, current efficiency and emission peak at a current density of 10 mA / cm 2, and the results are shown in Table 1 below.

샘플Sample 호스트Host 구동 전압(V)The driving voltage (V) EL 피크(nm)EL peak (nm) 전류효율(cd/A)Current efficiency (cd / A) 실시예 1Example 1 화합물 C-1Compound C-1 6.736.73 518518 41.841.8 실시예 2Example 2 화합물 C-2Compound C-2 6.736.73 518518 41.541.5 실시예 3Example 3 화합물 C-3Compound C-3 6.746.74 517517 41.341.3 실시예 4Example 4 화합물 C-4Compound C-4 6.646.64 516516 43.543.5 실시예 5Example 5 화합물 C-5Compound C-5 6.656.65 516516 41.741.7 실시예 6Example 6 화합물 C-6Compound C-6 6.666.66 516516 42.142.1 실시예 7Example 7 화합물 C-7Compound C-7 6.666.66 516516 38.838.8 실시예 8Example 8 화합물 C-8Compound C-8 6.96.9 517517 40.340.3 실시예 9Example 9 화합물 C-9Compound C-9 6.916.91 517517 40.240.2 실시예 10Example 10 화합물 C-10Compound C-10 6.756.75 516516 39.139.1 실시예 11Example 11 화합물 C-11Compound C-11 6.686.68 515515 39.239.2 실시예 12Example 12 화합물 C-12Compound C-12 6.696.69 517517 39.339.3 실시예 13Example 13 화합물 C-13Compound C-13 6.696.69 516516 39.439.4 실시예 14Example 14 화합물 C-14Compound C-14 6.716.71 515515 41.241.2 실시예 15Example 15 화합물 C-15Compound C-15 6.736.73 515515 41.241.2 실시예 16Example 16 화합물 C-16Compound C-16 6.756.75 516516 41.141.1 실시예 17Example 17 화합물 C-17Compound C-17 6.756.75 517517 4141 실시예 18Example 18 화합물 C-18Compound C-18 6.816.81 516516 40.640.6 실시예 19Example 19 화합물 C-19Compound C-19 6.836.83 518518 40.740.7 실시예 20Example 20 화합물 C-20Compound C-20 6.846.84 517517 40.840.8 실시예 21Example 21 화합물 C-21Compound C-21 6.856.85 516516 40.940.9 실시예 22Example 22 화합물 C-22Compound C-22 6.866.86 518518 40.940.9 실시예 23Example 23 화합물 C-23Compound C-23 6.876.87 516516 41.141.1 실시예 24Example 24 화합물 C-24Compound C-24 6.876.87 516516 41.241.2 실시예 25Example 25 화합물 C-25Compound C-25 6.886.88 517517 41.241.2 실시예 26Example 26 화합물 C-26Compound C-26 6.896.89 515515 41.341.3 실시예 27Example 27 화합물 C-27Compound C-27 6.896.89 517517 41.341.3 실시예 28Example 28 화합물 C-28Compound C-28 6.916.91 516516 41.841.8 실시예 29Example 29 화합물 C-29Compound C-29 6.916.91 518518 4242 실시예 30Example 30 화합물 C-30Compound C-30 6.76.7 518518 42.242.2 실시예 31Example 31 화합물 C-31Compound C-31 6.656.65 516516 42.642.6 실시예 32Example 32 화합물 C-32Compound C-32 6.666.66 516516 42.842.8 실시예 33Example 33 화합물 C-33Compound C-33 6.646.64 516516 41.341.3 실시예 34Example 34 화합물 C-34Compound C-34 6.886.88 516516 39.839.8 실시예 35Example 35 화합물 C-35Compound C-35 6.726.72 516516 40.540.5 실시예 36Example 36 화합물 C-36Compound C-36 6.626.62 518518 38.838.8 실시예 37Example 37 화합물 C-37Compound C-37 6.636.63 518518 40.640.6 실시예 38Example 38 화합물 C-38Compound C-38 6.656.65 518518 41.341.3 실시예 39Example 39 화합물 C-39Compound C-39 6.616.61 516516 41.641.6 실시예 40Example 40 화합물 C-40Compound C-40 6.736.73 517517 40.440.4 실시예 41Example 41 화합물 C-41Compound C-41 6.686.68 517517 40.940.9 실시예 42Example 42 화합물 C-42Compound C-42 6.626.62 517517 41.241.2 비교예 1Comparative Example 1 CBPCBP 6.936.93 516516 38.238.2

상기 표1에 나타낸 바와 같이, 본 발명에 따른 화합물 C-1 내지 C-4를 발광층의 호스트 물질로 사용하는 실시예 1 내지 42의 녹색 유기 EL 소자는, 종래 CBP를 사용하는 비교예 1의 녹색 유기 EL 소자보다 전류효율 및 구동전압 면에서 우수한 성능을 나타내는 것을 확인할 수 있었다.As shown in Table 1, the green organic EL devices of Examples 1 to 42, in which the compounds C-1 to C-4 according to the present invention were used as the host material of the light emitting layer, It was confirmed that the organic EL device exhibited better current efficiency and better driving voltage than the organic EL device.

이상을 통해 본 발명의 바람직한 실시예에 대하여 설명하였지만, 본 발명은 이에 한정되는 것이 아니고 특허청구범위와 발명의 상세한 설명의 범위 안에서 여러 가지로 변형하여 실시하는 것이 가능하고 이 또한 발명의 범주에 속하는 것은 당연하다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, It is natural.

Claims (7)

하기 화학식 1로 표시되는 화합물:
[화학식 1]
Figure 112015029267679-pat00117

(상기 화학식 1에서,
R1 내지 R5는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소, C1~C40의 알킬기, C6~C40의 아릴기 및 핵원자수 5 내지 40의 헤테로아릴기로 이루어진 군에서 선택되며,
다만, R1 및 R2, R2 및 R3, R3 및 R4 중 적어도 하나는 서로 결합하여 하기 화학식 2로 표시되는 축합고리를 형성하고,
[화학식 2]
Figure 112015029267679-pat00118

상기 화학식 2에서
X1은 O, S, Se, N(Ar2), C(Ar3)(Ar4) 및 Si(Ar5)(Ar6)으로 이루어진 군에서 선택되고;
Ar1 내지 Ar6는 각각 독립적으로 C6~C40의 아릴기 및 핵원자수 5 내지 40의 헤테로아릴기로 이루어진 군에서 선택되며;
R6 내지 R9는 서로 동일하거나 상이하며, 각각 독립적으로 수소, 중수소, C1~C40의 알킬기, C6~C40의 아릴기 및 핵원자수 5 내지 40의 헤테로아릴기로 이루어진 군에서 선택되며;
상기 R1 내지 R9의 알킬기, 아릴기 및 헤테로아릴기와, 상기 Ar1 내지 Ar6의 아릴기 및 헤테로아릴기는, 각각 독립적으로 C1~C40의 알킬기, C6~C40의 아릴기, 핵원자수 5 내지 40의 헤테로아릴기, C6~C40의 아릴아민기 및 C6~C40의 아릴실릴기로 이루어진 군으로부터 선택된 하나 이상의 치환기로 치환되거나 또는 비치환되고, 이때 치환기가 복수인 경우, 서로 동일하거나 상이할 수 있음).
A compound represented by the following formula (1):
[Chemical Formula 1]
Figure 112015029267679-pat00117

(In the formula 1,
R 1 to R 5 are the same or different from each other and each independently selected from the group consisting of hydrogen, deuterium, a C 1 to C 40 alkyl group, a C 6 to C 40 aryl group, and a heteroaryl group having 5 to 40 nuclear atoms And,
Provided that at least one of R 1 and R 2, R 2 and R 3 , R 3 and R 4 is bonded to each other to form a condensed ring represented by the following formula (2)
(2)
Figure 112015029267679-pat00118

In the formula (2)
X 1 is selected from the group consisting of O, S, Se, N (Ar 2 ), C (Ar 3 ) (Ar 4 ) and Si (Ar 5 ) (Ar 6 );
Each of Ar 1 to Ar 6 is independently selected from the group consisting of a C 6 to C 40 aryl group and a heteroaryl group having 5 to 40 nuclear atoms;
R 6 to R 9 are the same or different and each independently selected from the group consisting of hydrogen, deuterium, a C 1 to C 40 alkyl group, a C 6 to C 40 aryl group, and a heteroaryl group having 5 to 40 nuclear atoms ;
The alkyl, aryl and heteroaryl groups of R 1 to R 9 and the aryl and heteroaryl groups of Ar 1 to Ar 6 are each independently a C 1 to C 40 alkyl group, a C 6 to C 40 aryl group, nuclear atoms of 5 to 40 heteroaryl group, C 6 ~ substituted with C 40 arylamine group, and a C 6 ~ C 40 aryl silyl group with one or more substituents selected from the group consisting of or is unsubstituted, wherein the substituent is a plurality They may be the same or different from each other).
제1항에 있어서, 하기 화학식 3 내지 8로 이루어진 군에서 선택된 것으로 표시되는 화합물:
[화학식 3]
Figure 112014061340957-pat00119

[화학식 4]
Figure 112014061340957-pat00120

[화학식 5]
Figure 112014061340957-pat00121

[화학식 6]
Figure 112014061340957-pat00122

[화학식 7]
Figure 112014061340957-pat00123

[화학식 8]
Figure 112014061340957-pat00124

(상기 화학식 3 내지 화학식 8 에서,
R1 내지 R9, Ar1 및 X1은 각각 제1항에서 정의된 바와 같음).
The compound according to claim 1, which is selected from the group consisting of the following formulas (3) to (8):
(3)
Figure 112014061340957-pat00119

[Chemical Formula 4]
Figure 112014061340957-pat00120

[Chemical Formula 5]
Figure 112014061340957-pat00121

[Chemical Formula 6]
Figure 112014061340957-pat00122

(7)
Figure 112014061340957-pat00123

[Chemical Formula 8]
Figure 112014061340957-pat00124

(In the above Chemical Formulas 3 to 8,
R 1 to R 9 , Ar 1 and X 1 are as defined in claim 1, respectively.
제1항에 있어서, X1은 N(Ar2)이고,
Ar2는 제1항에서 정의한 바와 같은 것이 특징인 화합물.
The compound according to claim 1, wherein X 1 is N (Ar 2 )
Wherein Ar &lt; 2 &gt; is as defined in claim 1.
삭제delete 제1항에 있어서, 상기 Ar1 내지 Ar6는 각각 독립적으로 하기 치환기 A1 내지 A65로 이루어진 군에서 선택되는 것이 특징인 화합물:
Figure 112012102405784-pat00125

Figure 112012102405784-pat00126

Figure 112012102405784-pat00127

Figure 112012102405784-pat00128

Figure 112012102405784-pat00129

Figure 112012102405784-pat00130
The compound according to claim 1, wherein Ar 1 to Ar 6 are each independently selected from the group consisting of Substituents A 1 to A 65:
Figure 112012102405784-pat00125

Figure 112012102405784-pat00126

Figure 112012102405784-pat00127

Figure 112012102405784-pat00128

Figure 112012102405784-pat00129

Figure 112012102405784-pat00130
양극, 음극, 및 상기 양극과 음극 사이에 개재(介在)된 1층 이상의 유기물층을 포함하는 유기 전계 발광 소자에 있어서,
상기 1층 이상의 유기물층 중 적어도 하나는 제1항 내지 제3항, 제5항 중 어느 한 항에 기재된 화합물을 포함하는 것이 특징인 유기 전계 발광 소자.
1. An organic electroluminescent device comprising an anode, a cathode, and at least one organic material layer interposed between the anode and the cathode,
Wherein at least one of the one or more organic compound layers comprises a compound according to any one of claims 1 to 3 and 5.
제6항에 있어서, 상기 화합물을 포함하는 적어도 하나의 유기물층은 발광층인 것이 특징인 유기 전계 발광 소자.The organic electroluminescent device according to claim 6, wherein at least one organic compound layer containing the compound is a light emitting layer.
KR1020120142810A 2012-12-10 2012-12-10 New organic compounds and organic electro luminescence device comprising the same Expired - Fee Related KR101561332B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020120142810A KR101561332B1 (en) 2012-12-10 2012-12-10 New organic compounds and organic electro luminescence device comprising the same
PCT/KR2013/010483 WO2014092351A1 (en) 2012-12-10 2013-11-19 Novel organic compound and organic electroluminescent element comprising same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120142810A KR101561332B1 (en) 2012-12-10 2012-12-10 New organic compounds and organic electro luminescence device comprising the same

Publications (2)

Publication Number Publication Date
KR20140074634A KR20140074634A (en) 2014-06-18
KR101561332B1 true KR101561332B1 (en) 2015-10-26

Family

ID=50934590

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120142810A Expired - Fee Related KR101561332B1 (en) 2012-12-10 2012-12-10 New organic compounds and organic electro luminescence device comprising the same

Country Status (2)

Country Link
KR (1) KR101561332B1 (en)
WO (1) WO2014092351A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101229A1 (en) 2014-07-18 2016-11-30 Biogen Ma Inc IRAK4 INHIBITING AGENTS
KR102307359B1 (en) * 2014-12-22 2021-10-05 솔루스첨단소재 주식회사 Organic light-emitting compound and organic electroluminescent device using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005082701A (en) 2003-09-09 2005-03-31 Toyo Ink Mfg Co Ltd Organic electroluminescent device material and organic electroluminescent device using the same
WO2006047017A1 (en) 2004-09-20 2006-05-04 Janssen Pharmaceutica N.V. Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008218988A (en) * 2007-02-06 2008-09-18 Sumitomo Chemical Co Ltd Composition and light-emitting device using the composition
KR101894023B1 (en) * 2011-05-11 2018-10-05 삼성디스플레이 주식회사 Condensed-cyclic compound, organic light-emitting diode comprising the same, and flat display device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005082701A (en) 2003-09-09 2005-03-31 Toyo Ink Mfg Co Ltd Organic electroluminescent device material and organic electroluminescent device using the same
WO2006047017A1 (en) 2004-09-20 2006-05-04 Janssen Pharmaceutica N.V. Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators

Also Published As

Publication number Publication date
KR20140074634A (en) 2014-06-18
WO2014092351A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
KR101612164B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101998435B1 (en) Organic electro luminescence device
KR101601356B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR102508486B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20150061174A (en) Organic compounds and organic electro luminescence device comprising the same
KR101634852B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101571600B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101622811B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101618411B1 (en) Organic light-emitting compound and organic electroluminescent device comprising the same
JP6228979B2 (en) Organic light emitting compound and organic electroluminescent device using the same
KR102238282B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101634853B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101667449B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101612160B1 (en) Organic compound and organic electroluminescent device comprising the same
KR101548040B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101561332B1 (en) New organic compounds and organic electro luminescence device comprising the same
KR101390616B1 (en) Novel compounds and organic electro luminescence device using the same
KR101634849B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101571590B1 (en) Organic compounds and organic electro luminescence device using the same
KR101622809B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20150086107A (en) Organic compounds and organic electro luminescence device comprising the same
KR102384652B1 (en) Organic compound and organic electro luminescence device comprising the same
KR101810788B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR101585297B1 (en) Organic compounds and organic electro luminescence device comprising the same
KR20150141052A (en) Organic electro luminescence device

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20121210

PA0201 Request for examination
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140519

Patent event code: PE09021S01D

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141125

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150713

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20151012

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20151012

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20190723